Acknowledgements Bio-Rad by The Pennsylvania State University CiteSeerX Archives
  
Acknowledgements 
 
Bio-Rad 
Bioveta 
Merial 
Sanofi-Pasteur 
Virbac 
 
 
 
  Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
ii  Paris (France), 27-30 May 2007  
Contents 
■  Introduction ----------------------------------------------------------------------------------  1 
■  Objectives of the Conference--------------------------------------------------------------   2 
■  Topics-----------------------------------------------------------------------------------------   2 
■  Organisation of the Conference -----------------------------------------------------------  4 
■  General Information-------------------------------------------------------------------------  4 
■  Programme -----------------------------------------------------------------------------------  5 
■  Abstracts--------------------------------------------------------------------------------------  11 
KEYNOTE ADDRESS  
Towards the elimination of rabies in Eurasia: overview and perspectives---------------------------  12 
J. Blancou 
SESSION 1 – EPIDEMIOLOGICAL INFORMATION, RABIES IN EURASIA: REGIONAL REPORTS 
Map: Areas selected for regional reports ----------------------------------------------------------------   13 
Rabies situation in Western Europe -----------------------------------------------------------------------   14 
A.I. Wandeler 
Rabies situation in Eastern Europe-------------------------------------------------------------------------  15 
O. Matouch 
Rabies situation in Central Asia ----------------------------------------------------------------------------  16 
K.N. Gruzdev 
Rabies situation in the Middle East ------------------------------------------------------------------------   17 
A. Seimenis 
Rabies situation in Far East Asia  --------------------------------------------------------------------------  18 
Z.F. Fu 
SESSION 2 – RABIES PATHOGENESIS 
Cytokine expression in the CNS and periphery during infection with rabies ------------------------  19 
N. Johnson, K.L. Mansfield, D. Hicks, A. Nunez, D. Healy, S.M. Brookes, C. McKimmie,  
J.K. Fazakerley & A.R. Fooks 
Neuroimaging, virus and cytokine studies in rabies infected dogs -----------------------------------  20 
J. Laothamatas, S. Wacharapluesadee, B. Lumlertdacha,S. Ampawong, V. Tepsumethanon,  
P. Phumesin,S.Asavaphatiboon, L.Worapruekjaru, Y.Avihingsanon, N.Israsena & T.Hemachudha
Role of Calcitonin Gene-Related Peptide (CGRP) in the pathogenesis of rabies--------------------  21 
E. Weihe, M. Bette, M.A.R. Preuss, M. Faber, M.K. Schäfer, M.J. Schnell & B. Dietzschold 
Pathogenic and attenuated rabies viruses induce differential host protein expression in 
the central nervous system: implication of neuronal dysfunction-------------------------------------  22 
Z.F. Fu 
Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia”  
Paris (France), 27-30 May 2007  iii Dominance of a non-pathogenic over a pathogenic G protein gene in defining the  
pathogenicity of a rabies virus------------------------------------------------------------------------------  23 
B. Dietzschold 
SESSION 3 – RABIES PREVENTION AND CONTROL STRATEGIES 
Can rabies be eradicated? (Keynote speech)-------------------------------------------------------------   24 
C.E. Rupprecht, J. Barrett, D. Briggs, F. Cliquet, A.R. Fooks, B. Lumlertdacha, F.-X. Meslin, 
T. Müller, L.Nel, C. Schneider, N. Tordo & A. Wandeler 
Rabies Control in Dogs 
Molecular epidemiology of lyssaviruses in Eurasia -----------------------------------------------------  25 
L.M. McElhinney, D. Marston, S. Stankov, C. Tu, C. Black, N. Johnson, Y. Jiang, N. Tordo,  
T. Müller & A.R. Fooks 
Identification of novel canine rabies virus clades in the Middle East and North Africa-----------  26 
D. David, G.J. Hughes, B.A. Yakobson, I. Davidson, H. Un, O. Aylan, I.V. Kuzmin & C.E. Rupprecht 
Rabies in South Asia - Epidemiological investigation---------------------------------------------------  27 
C.K.Singh & B.S. Sandhu 
Stray dogs in Bangkok, Thailand: rabies virus infection and rabies antibody prevalence --------  28 
S. Kasempimolporn, B. Sichanasai, W. Saengseesom, S. Puempumpanich,  
S. Chatraporn & V. Sitprija  
Preference for commercially produced oral rabies baits by feral dogs ------------------------------  29 
D. Bergman, S. Bender, D. Slate, C. Rupprecht, K. Wenning, C. Heuser, S. Joe & T. Deliberto 
Assessment of the efficacy of oral vaccination of shepherd dogs in supplement of oral rabies 
vaccination of wild canids in Israel------------------------------------------------------------------------  30 
B. A. Yakobson, R. King, N. Sheihat & D. David  
Longterm immunization of recombinant rabies-canine adenovirus type-2 in dogs after  
intranasal or oral vaccination-------------------------------------------------------------------------------  31 
S.F. Zhang, Y. Liu, A.R. Fooks, F. Zhang & R.L. Hu  
New steps in the control of canine rabies in India ------------------------------------------------------  32 
H.K. Pradhan, J.P. Gurbuxani, F. Cliquet, B. Pattnaik, S.S. Patil, A. Regnault, H. Begouen,  
A.L. Guiot, R. Sood, P. Mahl, R. Singh, E. Picard, M.F.A. Aubert, J. Barrat & F.-X. Meslin
Rabies in Mexico, 1990-2005------------------------------------------------------------------------------  33 
C.H. Álvarez Lucas 
Risk of rabies introduction by non-commercial movement of pets------------------------------------  34 
P. Have, l. Alban, L.T. Berndtsson, F. Cliquet, P. Hostnik, S.C. Rodeia & M. Sanaa  
Rabies Control in Wildlife 
Epidemiology of rabies in South East Europe-------------------------------------------------------------  35 
N. Johnson, C. Freuling, A. Vos, H. Un, R. Valtchovski, M. Turcitu, F. Dumitrescu, V. Vlad, 
R. Velic, V. Sandrac, O. Aylan, T. Müller & A.R. Fooks 
Rabies in Mongolian steppes -------------------------------------------------------------------------------  36 
A.D. Botvinkin, D. Otgonbaatar, S. Tsoodol & I.V. Kuzmin  
Epidemiology and control of rabies in Iran ---------------------------------------------------------------  37 
A.R. Janani & A. Fayaz  
Rabies epidemiology in raccoon dogs and foxes --------------------------------------------------------  38 
A. Singer, K. Kauhala, K. Holmala & G.C. Smith  
Downside risk of wildlife translocation--------------------------------------------------------------------  39 
R. Chipman, D. Slate, C. Rupprecht & M. Mendoza  
Sylvatic rabies in Russia with special attention to perspectives of oral vaccination of  
wild carnivores------------------------------------------------------------------------------------------------  40 
A. D. Botvinkin, D.V. Bankovsky & G.A. Safonov  
  Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
iv  Paris (France), 27-30 May 2007 Finnish-Russian collaboration programme on rabies control in wildlife: the outcome of  
five years and the future prospects ------------------------------------------------------------------------  41 
A.E. Metlin, S.S. Rybakov, K.N. Gruzdev, V.V. Mikhalishin, A. Huovilainen & E. Neuvonen  
Rabies eradication programme in Estonia by means of oral vaccination of wildlife: first  
results-----------------------------------------------------------------------------------------------------------  42 
E. Niin, M. Laine & A. Pärtel  
Rabies surveillance in Poland between 1992 - 2006---------------------------------------------------  43 
M. Smreczak, P. Trębas, A. Orlowska & J.F. Żmudziński  
Efficacy of a square V-RG vaccine baits in red fox, domestic dog and raccoon dog---------------  44 
F. Cliquet, A.L. Guiot, C. Schumacher, J. Maki & J. Barrat  
Scenario-analysis evaluating emergency strategies after rabies re-introduction ------------------  45 
H.-H. Thulke, D. Eisinger, T. Selhorst & T. Müller  
The financial challenge to keep a large region free of rabies – the EU example-------------------  46 
C. Freuling, T. Selhorst & T. Müller  
What is the future of rabies control in Europe? ----------------------------------------------------------  47 
G.C. Smith, H.-H. Thulke, A.R. Fooks, M. Artois, D.W. Macdonald, D. Eisinger & T. Selhorst  
The strength of 70% - revising a given threshold of rabies control ----------------------------------  48 
H.-H. Thulke & D. Eisinger  
Rabies in Bats: an emerging zoonosis 
A random grid based molecular epidemiological study on EBLV isolates from Germany----------  49 
C. Freuling, T. Selhorst, L. Geue, D. Marston, N. Johnson, A.R. Fooks, N. Tordo & T. Müller 
Asymptomatic rhabdovirus infection in meridional serotine bats (Ep esicus isabel nus)   t li
from Spain------------------------------------------------------------------------------------------------------  50 
J.E. Echevarría, S. Vázquez-Morón, C. Ibáñez, J.C. Aznar, E. Ruiz & J. Juste 
Public health hazard of European bat lyssavirus, the Netherlands -----------------------------------  51 
W.H.M. Van Der Poel, K. Takumi, E.R.A.M. Verstraten, P.H.C. Lina,  
J. Van Der Giessen & J.A. Kramps  
Serological investigation of bats infected with rabies virus in China --------------------------------  52 
L. Wang, Y. Jiang, Z. Lu, K. Sun, H. Xuan, A. Fooks & C. Tu  
Epidemiology and pathogenicity of African bat lyssaviruses-------------------------------------------  53 
W. Markotter, C. Wilsenach & L.H. Nel et al. 
Experimental infection of big brown bats (Eptesicus fuscus) with West Caucasian  
bat virus --------------------------------------------------------------------------------------------------------  54 
I.V. Kuzmin, R. Franka & C.E. Rupprecht 
Susceptibility of foxes (Vulpes vulpes) to European bat lyssaviruses types-1 and -2 -------------  55 
F. Cliquet, E. Picard, J. Barrat, S.M. Brookes, D.M. Healy & A.R. Fooks  
Identification of British bat species using sequence comparison and its application to  
European bat lyssavirus diagnosis and surveillance----------------------------------------------------  56 
S.L. Harris, N. Johnson, S.M. Brookes, A.R. Fooks & G. Jones 
Rabies Prevention in Humans 
Human rabies includes early generalized vasospasm of cranial arteries that responds to 
tetrahydrobiopterin, l-arginine or nitroprusside----------------------------------------------------------  57 
R.E. Willoughby, A. Roy-Burman, K.W. Martin, J.C. Christensen, D.F. Westenkirchner, C. Glaser,  
C.E. Rupprecht & K. Hyland  
Therapy of human rabies: lessons from experimental studies in a mouse model-------------------  58 
A.C. Jackson, C.A. Scott, J. Owen, S.C. Weli & J.P. Rossiter 
Rabies control and prevention in Georgia: current status and perspectives-------------------------  59 
P. Imnadze, V. Surguladze, T. Tushishvili & l. Baidoshvili  
Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia”  
Paris (France), 27-30 May 2007  v A simplified economical 4-site intradermal post-exposure rabies vaccine regimen is as  
immunogenic as the current intramuscular and intradermal methods--------------------------------  60 
M.J. Warrell, A. Riddell, L.-M. Yu, J. Phipps, L. Diggle, J. Deeks, H. Bourhy, l. Audry, A.R. Fooks,  
S. Brookes, F.-X. Meslin, R. Moxon, A.J. Pollard & D.A. Warrell 
Single dose for rabies pre-immunization------------------------------------------------------------------  61 
P. Khawplod, H. Wilde, T. Kamolthum, Tantawichien & V. Sitprija  
Immune memory after remote pre- and post-exposure rabies vaccination: a prospective  
study in Thailand----------------------------------------------------------------------------------------------  62 
H. Wilde  
Epidemiology and prophylaxis of rabies in humans in France. Evaluation and perspectives  
Of a twenty five year surveillance program ---------------------------------------------------------------  63 
Y. Rotivel, M. Goudal, A. Simons de Fanti, D. Van Der Vliet & French Rabies Treatment Centres 
SESSION 4 – ADVANCES IN TECHNOLOGIES, DIAGNOSIS AND VACCINES 
Immune evasion, a critical strategy for rabies virus (Keynote speech) ------------------------------  64 
M. Lafon 
BHK-21 cell culture rabies vaccine - a candidate vaccine for humans------------------------------  65 
D. Lalosevic & V. Lalosevic 
Factors influencing the antibody response to rabies vaccination-------------------------------------  66 
V. Jakel, K. Cussler, M. König & H.-J. Thiel 
Attaining raccoon rabies management goals: history and challenges--------------------------------  67 
D. Slate, C.E. Rupprecht, D. Donovan, J. Badcock, A. Messier, R. Chipman & M. Mendoza 
Evaluation of the stability of rabies vaccine baits – field trial-----------------------------------------  68 
P. Mačiulskis, K. Lukauskas, E. Jacevičius, V. Kiudulas, J. Jokimas & A. Pockevičius 
Immunogenicity of ERA G 333 strain in foxes and raccoon dogs--------------------------------------  69 
D. Bankovskiy, G. Safonov & Y. Kurilchuk 
Canine adenovirus-based vaccines against rabies------------------------------------------------------  70 
N. Tordo, A. Fournier, C. Jallet, M. Szelechowski, B. Klonjkowski & M. Eloit 
Development of an edible rabies vaccine in maize, using vnukovo strain---------------------------  71 
E. Loza-Rubio, E. Rojas-Anaya, l. Gómez Nieto, M.T.J. Olivera Flores & M.A. Gómez 
Genetically engineered single-chain antibody fusion proteins for detection of rabies 
virus antigen---------------------------------------------------------------------------------------------------  72 
M. Mousli, I. Turki, H. Kharmachi & K. Dellagi 
Use of rabies virus as a transneuronal tracer of neuronal connections: implications for the 
understanding of rabies pathogenesis---------------------------------------------------------------------  73 
G. Ugolini 
Inhibition of rabies virus replication by Micro-RNA -----------------------------------------------------  74 
N. Israsena, N. Ratanasetyuth, P. Supavonwong, P. Virojanapirom & T. Hemachudha 
SESSION 5 – GENERAL CONCLUSIONS AND RECOMMENDATIONS 
Rabies at the Dawn of the 21st Century (Keynote speech)---------------------------------------------  75 
H. Koprowski 
OIE Guidelines on the control of dog populations--------------------------------------------------------  76 
S. Kahn, L. Stuardo & S.A. Rahman 
What have we achieved? The way forward (Keynote speech) -----------------------------------------  77 
D.J. Briggs 
 
 
  Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
vi  Paris (France), 27-30 May 2007 ■  Posters----------------------------------------------------------------------------------------- 79 
Don’t forget rabies when you settle abroad or travel with children----------------------------------------------  80 
M. Goudal & Y. Rotivel 
Determination of thermostability and melting point of the bait casing for the vaccine lysvulpen ----------  81 
V. Vrzal 
Ten-day oservation of live-rabid dogs--------------------------------------------------------------------------------  82 
V. Tepsumethanon, H. Wilde & V. Sitprija 
A simple sandwich ELISA (WELYSSA) for the detection of lyssavirus nucleocapsid in rabies suspected 
specimens using mouse monoclonal antibodies--------------------------------------------------------------------  83 
G. Xu, P. Weber, Q. Hu, H. Xue, L. Audry, C. Li, J. Wu & H. Bourhy 
Rabies research trends in the fgi “Federal Centre For Animal Health” -----------------------------------------  84 
S.S. Rybakov, A.E. Metlin, A.V. Borisov, A.N. Balashov, A.A. Egorov & K.N. Gruzdev 
RFFIT-modified antibody-binding test (ABTmR) as a fast and reproducible test for determination of  
potency of inactivated purified non-adjuvanted rabies vaccines for human use  -----------------------------  85 
S. Stankov, V. Simin, D. Vujin, U. Ungurović, N. Vranješ & J. Desnica 
Comparative analysis of the full genome sequence for EBLV -1 and -2 with other lyssaviruses------------  86 
D.A. Marston, L.M. McElhinney, N. Johnson, T. Müller, K.K. Conzelmann, N. Tordo & A.R. Fooks
Overview of rabies in Greece from 1966 to 2006------------------------------------------------------------------  87 
O. Mangana, K. Nomikou, P. Lliadou & G. Anastasiadis 
Bayesian estimation of rabies ab-ELISA performances in absence of a gold standard-----------------------  88 
S. Guillossou, M. Rabilloud, S. Leterme & R. Ecochard 
The first case of European bat lyssavirus type 1b infection in E. sero inus in Poland -----------------------  89  t
M. Smreczak, A. Orłowska, P. Trębas & J.F.Żmudziński 
Preliminary results of an active survey of bat rabies in Belgium ------------------------------------------------  90 
L. Audry, F. Klein & H. Bourhy 
Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine-----------------  91 
R.L. Hu, Y. Liu, S.F. Zhang & F. Zhang 
Profile epidemiologist and molecular characterization of the rabies virus during the period of  
1996 -2006 in the estate of Mexico, MEXICO ----------------------------------------------------------------------  92 
F.G. Bastida-González, J.M. Jiménez-Estrada, M.D. Hernández-Ramírez, G. Arteaga-Troncoso,  
F. Guerra-Infante, A. Meléndez-Felix, J.L. Rubí-Salazar & M.E. Barrera-Tapia 
Active monitoring of EBLV infection in natural bat colonies------------------------------------------------------  93 
B. Amengual, H. Bourhy, M. López-Roig & J. Serra-Cobo 
Comparative studies of an inactivated vaccines against rabies virus in vaccinated goats -----------------  94 
N. Knezevic, S. Stankov, L.J. Veljovic, B. Djuricic, L.J. Lazarevic & L.J. Pausak 
Platelia
TM Rabies II: an ELISA assay used for titration of rabies glycoprotein antibodies comparable  
to the reference method RFFIT ----------------------------------------------------------------------------------------  95 
M. Feyssaguet, L. Dacheux, L. Audry, I. Blanchard & H. Bourhy 
Platelia
TM Rabies II: an ELISA assay to complete current methods for titration of rabies glycoprotein 
antibodies in animal samples------------------------------------------------------------------------------------------  96 
A. Servat, M. Feyssaguet, F. Boué, I. Blanchard & F. Cliquet 
Development of a sequence database for European bat variants of rabies virus identified in  
Eurasia --------------------------------------------------------------------------------------------------------------------  97 
A.R. Fooks, L.M. McElhinney, D. Marston & all members of medvetnet wp05 
An outbreak of pig rabies in Hunan province of China ------------------------------------------------------------  98 
Y. Jiang, X. Yu, L. Wang, H. Xuan, Z. Hu & C. Tu
Isolation of European bat lyssaviruses (EBLVS) on neuroblastoma cells in comparison with mouse  
inoculation test ----------------------------------------------------------------------------------------------------------  99 
J.A. Kramps, E. Van Weezep, E.R.A.M. Verstraten, W.H.M. Van Der Poel & E.A. Kooi 
Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia”  
Paris (France), 27-30 May 2007  vii Rabies surveillance, diagnosis and eradication in Austria -------------------------------------------------------  100 
E. Vanek, Z. Bagó, S. Revilla-Fernández, E. Wodak, J. Weikel & A. Höflechner 
A rabies cell phone advisory system: a culturally targeted tool designed to reduce human rabies  
suffering in the Philippines  -------------------------------------------------------------------------------------------  101 
E. Adriano, M. Vinluan & S.J. Scholand
Raccoon dog rabies in Poland-----------------------------------------------------------------------------------------  102 
M. Sadkowska-Todys, M. Rosinska, M. Czerwinski, M. Smreczak & J.F. Zmudzinski 
Implementation of ultra-light aircrafts in baits distribution for per-oral vaccination of venison 
against rabies------------------------------------------------------------------------------------------------------------  103 
M. Sinkovic, D. Bosiljka & D. Lalosevic 
Retrospective analysis of 174 humans who received P.E.P. (rabies immunoglobulin (RIG) and vaccine)  104 
M. Goudal, Y. Rotivel, A. Simmons De Fantis & D. Van Der Vliet 
Epidemiology of rabies in the Kyrgyz Republic  --------------------------------------------------------------------  105 
E.K. Akmatova, R.Z. Nurgaziev & N.T. Dzhaparaliev 
Antibody response in italian dogs vaccinated with inactivated vaccines  -------------------------------------  106 
F. Monaco, G. Savini, A. Ripani, P.M. Franchi, R. Lelli 
■  List of participants --------------------------------------------------------------------------  107 
 
 
 
  Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
viii  Paris (France), 27-30 May 2007  
Introduction 
The theme of this second Conference on rabies hosted by the OIE in collaboration with the WHO and 
EU - Towards the elimination of rabies in Eurasia - signifies the commitment of the World Organisation 
for Animal Health to prevent and control animal diseases and zoonoses worldwide. Following the very 
successful first Conference on rabies, held in Kiev in 2005, this Conference aims to take the 
recommendations of the Kiev Conference one step further by seeking answers to questions on how we 
could proceed towards the eventual elimination of this most feared zoonotic disease - not only in 
Eurasia but all over the globe. 
In spite of rapid advances in diagnostics, vaccine development and the application of novel 
technologies to controlling the disease, rabies remains a significant cause of death in humans following 
exposure to rabid animals. It is therefore the prime responsibility of the veterinary profession to apply 
its knowledge and skills in animal disease control to creating a buffer between the animal source of the 
disease and susceptible human beings. An important prerequisite to achieving this goal is the ability of 
the veterinary services of countries to institute and apply the international standards for the control of 
animal diseases and zoonoses. The OIE, fully realizing the need of many developing and in-transition 
countries to improve the governance and delivery of their veterinary services, has embarked on a global 
campaign to publicise the importance of accepting the delivery of veterinary services as an international 
public good. Only by assisting countries in need to apply the minimum standards for animal disease 
control will we be able to fully benefit from the advantages of new technologies to eventually move 
towards the elimination of rabies. 
This Conference brings together veterinarians, researchers and regulatory officials in both animal and 
public health to not only share their experiences but also to confirm their common commitment to 
adding rabies to the list of diseases that have been successfully controlled and eliminated by the 
veterinary profession. The Conference will highlight important epidemiological developments on the 
disease in Eurasia and will share the experiences and opinions of experts on the prevention and control 
of rabies in dogs, wildlife and bats; the prevention of the disease in humans and cooperation between 
public health and animal health authorities; advances in technologies and vaccine development. 
I am convinced that the veterinary profession, together with their colleagues in the public health sector, 
has the ability, knowledge, expertise and commitment to realise the ideal of this Conference and to 
conclude what Pasteur started when he developed the first rabies vaccine more than a century ago. 
 
Dr Bernard Vallat 
OIE Director General 
 
 
Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
 Paris (France), 27-30 May 2007  1 Objectives of the Conference 
•  To consider the strategies and policies for the elimination of human and animal rabies in Eurasia.  
•  The target audience of the conference will be regulatory veterinary services, public health services, 
medical and veterinary practitioners, scientists and researchers.  
•  The main topics included on the agenda of the Conference are: 
• Epidemiology 
• Rabies  pathogenesis 
•  Rabies control in dogs 
•  Rabies control in wildlife 
•  Bat rabies an emerging zoonosis 
• Human  rabies  prevention 
•  Advances in technologies, diagnosis and vaccines 
Topics 
Epidemiology 
The aim of this session is to provide up-to-date information on rabies across Eurasia and to serve as a 
basis for the other conference topics. Therefore, the principal item of this session will be selected 
regional reports on the rabies situation from 5 different geographic regions in Europe and Asia, e.g. 
Western Europe, Eastern Europe, Middle East, Central Asia and the Far East, in recent years, which will 
be given by representative speakers. The regional reports will include aspects of rabies infection in man 
and animals, surveillance and epidemiology of rabies based on information of a questionnaire to be 
sent to the participating countries. Of particularly relevance is the holistic epidemiological picture of 
rabies in Eastern Europe and Asia. 
Rabies pathogenesis 
The overall aim of this session is to provide an understanding of the basic mechanisms of rabies virus - 
host interactions which is imperative for the prevention of rabies in humans and its control in animal 
populations. It includes fundamental research on the function and antigenic analysis of virus structural 
components, on virus genome structure and expression, on analysis of virus replication processes and 
on effects of virus on their host cells. Of special interest is the modulation of cellular function, the 
initiation of innate and humoral immune response in the early spread of rabies virus and the immune 
evasion. Also, the role of the blood-brain barrier in the pathogenesis and the clearance of rabies virus 
from the central nervous system will be addressed. 
Rabies control in dogs 
Domestic dogs are the principal hosts for classical rabies virus in many parts of the world, e.g. Africa, 
Latin America, Middle East and Asia. Genetic and antigenic tools will improve our understanding of the 
molecular and antigenic epidemiology of carnivora rabies in Eurasia. Past experience has clearly 
demonstrated that eliminating rabies in the dog population can substantially reduce human infection. 
The tools required to eliminate canine rabies were developed several years ago but have not been used 
collectively in a stepwise strategic manner to eliminate rabies in the canine population in Asia where 
tens of thousands of humans still die every year. Therefore, areas for discussion for this topic will 
mainly focus on: molecular and antigenic epidemiology of carnivora rabies in Eurasia, whether canine 
rabies is really independent from a wildlife reservoir, dog rabies control using parenteral vaccination, 
oral vaccination of stray dogs, and complementary measure to control the dog population such as 
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responsible dog ownership, the control of food resources, sterilization of dogs (ABC programs), 
establishment of animal shelters and culling. Field trials throughout Eurasia in places where dog 
accessibility to parenteral vaccination has been identified as the obstacle to rabies elimination are also 
encouraged. 
Rabies control in wildlife 
Areas for discussion for this topic will focus on sophisticated and modern methods of rabies control in 
various rabies wildlife reservoirs especially foxes and raccoon dogs. Rabies control by oral vaccination 
will be of high significance and will encompass oral vaccination programmes currently implemented, 
field trials, and evaluation of bait delivery systems. Also, oral vaccine safety and efficacy in target and 
non-target species, bait development and bait preference trials will be addressed. For those concerned 
with planning of vaccination campaigns, a number of requirements regarding vaccination strategies, 
efficacy, optimization and economics of bait delivery are of particular value. Data on field trials on the 
optimization of oral vaccination campaigns will be of interest. New molecular studies of rabies virus 
variants circulating in wildlife will complete the picture. 
Bat rabies an emerging zoonosis 
Bat variants of rabies virus are of increasing public health importance worldwide. Intriguingly, bats are 
reservoir and vector for six out of the seven genotypes characterized so far. Four recent isolates of Asian 
bat lyssaviruses are proposed as new genotypes and new isolates from bats are expected. This session, 
which follows OIE and the WHO recommendations for future research considerations on bat rabies, is 
aiming to encompass aspects of bat lyssavirus infections and to contribute to increasing international 
attempts to unveil the risk of bat lyssaviruses for humans. Presentations on updating existing bat rabies 
data and original works on (i) passive and active surveillance of bat rabies, (ii) molecular epidemiology 
and antigenic profile of bat lyssavirus isolates throughout Eurasia, (iii) identification of spill-over 
infections and (iv) studies on the pathogenicity of those viruses for bats and other terrestrial animals 
are welcome. 
Human rabies prevention 
This topic serves as an interface between public health authorities, those in research and development, 
medical practitioners and other workers in the field. Relevant contributions will range from basic 
research through to applications, safety and recommendations. Key aspects are vaccines for human 
use, vaccine responses, immunization schedules for preventative vaccination and post-exposure 
prophylaxis as well as the use of hyperimmune gamma-globulin or immune serum in post-exposure 
prophylaxis (PEP) for both terrestrial and bat rabies. Studies on the use of monoclonal antibodies to 
replace hyperimmune sera for PEP and recent advances in therapy will be discussed. Also, ways to 
improve collaboration between public health and veterinary authorities with respect to human rabies 
prevention should be discussed. 
Advances in technologies, diagnosis and vaccines 
Basic and technologic research should ideally find application into field problems. This pre-eminent 
topic is intended for those interested in the most recent developments in rabies prevention and therapy, 
using vaccines, antivirals as well as any basic study aiming at improving the related knowledge. 
Diagnosis improvement will be discussed, principally the recent advances on detection, identification 
and precise quantification of lyssavirus isolates and load in infected organs using molecular or other 
techniques. Furthermore, standardization and harmonization of diagnostic procedures and quality 
assurance (ring tests) will be addressed. 
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General information 
Presentations 
-  Invited keynote speakers will provide a summary overview of each main topic. 
-  Abstracts were selected for oral presentations. 
-  Selected posters will be displayed throughout the conference. 
-  All the abstracts selected for oral presentations, the best posters, conclusions and recommendations 
will be published in the Proceedings of the Conference. 
Venue 
The Conference will be held at the OIE Headquarters. 
World Organisation for Animal Health (OIE) 
12 rue de Prony  
75017 Paris, France  
Tel.: 33 (0) 1 44 15 18 88 
Fax: 33 (0) 1 42 67 09 87 
Language 
The Conference will be conducted in English, simultaneous translation into Russian and French will be 
provided. 
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Programme 
Sunday, 27 May 2007 
OIE Headquarters, Salle Vittoz 
16h00 - Registration 
18h00 - Opening Ceremony  
  Chairperson: G. Brückner (OIE, France) 
 Welcome 
  B. Vallat, Director General, OIE 
F.-X. Meslin, Coordinator Zoonoses and VPH, WHO 
J.-P. Vermeersch, European Commission 
 
Keynote address: Towards the elimination of rabies in Eurasia: Overview and perspectives 
J. Blancou 
 
19h00 - OIE Welcome cocktail 
 
Monday, 28 May 2007 
OIE Headquarters, Salle Vittoz 
09h00 - Session 1 / Epidemiological information. Rabies in Eurasia: Regional reports 
Chairperson: V. Caporale (IZS, Italy) - Rapporteur: B. Dodet (IABs, Switzerland) 
 
09h00  Rabies situation in Western Europe    A.I. Wandeler (CFIA/ACIA, Canada) 
09h12  Rabies situation in Eastern Europe    O. Matouch (NRLR, Czech Rep.)
09h24  Rabies situation in Central Asia    K.N.Gruzdev (FGI-ARRIAH, Russia)
09h36  Rabies situation in the Middle East    A. Seimenis (WHO) 
09h48  Rabies situation in Far East Asia    Z.F. Fu (UG, USA) 
10h00 Discussion 
10h30 Coffee  break 
11h00 - Session 2 / Rabies pathogenesis 
Chairperson: A.C. Jackson (KGH, Canada) - Rapporteur: M. Lafon (IP, France) 
11h00  Cytokine expression in the CNS and periphery     N. Johnson (VLA, UK) 
during infection with rabies 
11h10  Neuroimaging, virus and cytokine studies in     T. Hemachudha (CU, Thailand) 
rabies infected dogs 
11h20  Role of Calcitonin Gene-Related Peptide (CGRP)     E. Weihe (UM, Germany) 
in the pathogenesis of rabies 
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11h30 Pathogenic  and  attenuated rabies viruses     Z.F. Fu (UG, USA) 
induces differential host protein expression in  
the central nervous system: Implication of 
neuronal dysfunction 
11h40  Dominance of a non-pathogenic over a pathogenic     B. Dietzschold (TJU, USA) 
  G protein gene in defining the pathogenicity of 
  a rabies virus 
11h50 Discussion 
12h00 Lunch  break 
13h30 - Session 3 / Rabies prevention and control strategies 
 
13h30  Keynote speech: Can rabies be eradicated?      C.  Rupprecht  (CDC, USA) 
 
14h00 - Rabies control in dogs 
Chairperson: F. Cliquet (AFSSA, France) - Rapporteur: B.A. Yakobson (KVI, Israël) 
14h00  Molecular epidemiology of lyssaviruses in  
 Eurasia  L.M.  McElhinney (VLA, UK) 
14h10  Identification of novel canine rabies virus     D. David, (KVI, Israël) 
clades in the middle east and north africa 
14h20  Rabies in South Asia - Epidemiological     C.K. Singh (RRDL, India) 
investigations 
14h30  Stray dogs in Bangkok, Thailand: rabies virus     S. Kasempimolporn (QSMI, Thailand) 
infection and rabies antibody prevalence 
14h40  Preference for commercially produced oral     D. Bergman (USDA, USA) 
rabies baits by feral dogs 
14h50  Assessment of the efficacy of oral vaccination     B.A. Yakobson (KVI, Israël) 
of shepherd dogs in supplement of oral rabies  
vaccination of wild canids in israel 
15h00  Longterm immunization of recombinant rabies-     R. Hu (AMMS,China) 
 canine adenovirus type-2 in dogs after intranasal 
 or oral vaccination 
15h10  New steps in the control of canine rabies in     H.K. Pradhan (IVRI, India) 
India    F.-X. Meslin (WHO) 
15h20  Rabies in Mexico, 1990-2005    C.H. Álvarez Lucas (SM, Mexico) 
15h30 Risk of rabies introduction by non-commercial    P. Have (EFSA) 
movement of pets 
15h40 Discussion 
16h00  Coffee break  
16h30 - Rabies control in wildlife 
Chairperson: A.D. Botvinkin (ISMV, Russia) - Rapporteur: I. Kuzmin (CDC, USA) 
16h30  Epidemiology of rabies in South East Europe    N. Johnson (VLA, UK) 
16h40  Rabies in Mongolian steppes    A.D. Botvinkin (ISMV, Russia) 
16h50  Epidemiology and control of rabies in Iran    A.R. Janani (PI, Iran) 
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17h00  Rabies epidemiology in Raccoon Dogs and Foxes    A. Singer (CSL, UK) 
17h10  Downside risk of wildlife translocation    R. Chipman (USDA, USA) 
17h20  Sylvatic rabies in Russia with special attention to    A.D. Botvinkin (ISMV, Russia) 
perspectives of oral vaccination of wild carnivores  
17h30  Finnish-Russian collaboration programme on    A. Metlin (FGI ARRIAH, Russia) 
rabies control in wildlife: the outcome of five  
years and the future prospects 
17h40  Rabies eradication programme in Estonia by    M. Laine (FB, Estonia) 
means of oral vaccination of wildlife: first results 
17h50  Rabies surveillance in Poland between 1992 –    M. Smreczak (NVRI, Poland) 
 2006 
18h00  Efficacy of a square presentation of V-RG vaccine    F. Cliquet (AFSSA, France) 
baits in red fox, domestic dog and raccoon dog 
18h10 Scenario-analysis  evaluating  emergency strategies   H.-H. Thulke (HCER, Germany) 
after rabies re-introduction 
18h20  The financial challenge to keep a large region    T. Müller (FLI, Germany) 
free of rabies – the EU example 
18h30  What is the future of rabies control in Europe?    G. Smith (CSL, K) 
18h40  The strength of 70% - Revising a given threshold    H.-H. Thulke (HCER, Germany) 
of rabies control 
18h50 Discussion 
 
Tuesday, 29 May 2007 
09h00 - Rabies in bats: an emerging zoonosis 
Chairperson: A.R. Fooks (VLA, UK) - Rapporteur: T. Müller (FLI, Germany) 
09h00  A random grid based molecular epidemiological     C. Freuling (FRIAH, Germany) 
study on EBLV isolates from Germany 
09h10  Asymptomatic rhabdovirus infection in meridional   J.E. Echevarría Mayo (ISC, Spain) 
serotine bats (Eptesicus isabellinus) from Spain 
09h20 Public  health  hazard  of European bat lyssavirus,     W.H.M. Van der Poel (WUR, Netherlands) 
the Netherlands 
09h30  Serological investigation of bats infected with     C. Tu (AMMS, China) 
rabies virus in China 
09h40  Epidemiology and pathogenicity of African bat     L.H. Nel (UP, South Africa) 
lyssaviruses 
09h50  Experimental infection of big brown bats    I. Kuzmin (CDC, USA) 
(Eptesicus fuscus) with West Caucasian bat virus 
10h00  Susceptibility of foxes (Vulpes vulpes) to European   E. Picard, (AFSSA, France) 
bat lyssaviruses types-1 and -2 
10h10  Identification of british bat species using sequence  S.L. Harris (UB, UK) 
comparison and its application to european bat  
lyssavirus diagnosis and surveillance 
10h20 Discussion 
10h30 Coffee  break 
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11h00 - Rabies prevention in humans 
Chairperson: F.-X. Meslin (WHO) - Rapporteur: Y. Rotivel (IP, France) 
 
11h00  Human rabies includes early generalized     R. Willoughby (CHW, USA) 
vasospasm of cranial arteries that responds to  
tetrahydrobiopterin, l-arginine or nitroprusside 
11h10  Therapy of human rabies: lessons from experimental   A.C. Jackson (KGH, Canada) 
studies in a mouse model 
11h20  Rabies control and prevention in the republic of     P. Imnadze (NCCD, Georgia) 
Georgia: current status and perspectives 
11h30  A simplified economical 4-site intradermal  M. Warrell (UO, UK) 
post-exposure rabies vaccine regimen is as 
immunogenic as the current intramuscular and 
intradermal methods 
11h40  Single dose for rabies pre-immunization   P.  Khawplod  (QSMI, Thailand) 
11h50  Immune memory after remote pre- and     H. Wilde (CU, Thailand) 
post-exposure rabies vaccination: a prospective  
study in thailand 
12h00  Epidemiology and prophylaxis of rabies in humans   Y. Rotivel (IP, France) 
in France. Evaluation and perspectives of a twenty 
five year surveillance program 
12h10 Discussion 
12h30 Lunch  break 
14h00 - Session 4 / Advances in technologies, diagnosis and vaccines 
Chairperson: N. Tordo (IP, France) - Rapporteur: T. Hemachuda (CU, Thailand) 
 
14h00  Keynote speech: Immune evasion, a critical strategy    M. Lafon (IP, France) 
for rabies virus 
14h30  BHK-21 cell culture rabies vaccine- a candidate     D. Lalosevic (FMNS, Serbia) 
vaccine for Humans 
14h40  Factors influencing the antibody response to     V. Jakel (JLU, Germany) 
rabies vaccination 
14h50  Attaining raccoon rabies management goals:    D. Slate (USDA, USA) 
history and challenges 
15h00  Evaluation of the stability of rabies vaccine baits     P. Maciulskis (LVA, Lithuania) 
field trial 
15h10  Immunogenicity of ERA G 333 strain in foxes and   D. Bankovskiy (ARRI, Russia) 
raccoon dogs 
15h20  Canine adenovirus-based vaccines against rabies    N. Tordo (IP, France) 
15h30 Coffee  break 
16h00  Development of an edible rabies vaccine in maize,    E. Loza-Rubio (NCVM, Mexico) 
using vnukovo strain 
16h10  Genetically engineered single-chain antibody    M. Mousli (IP, Tunisia) 
fusion proteins for detection of rabies virus antigen 
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16h20  Use of rabies virus as a transneuronal tracer of    G. Ugolini (CNRS, France) 
neuronal connections: Implications for the  
understanding of rabies pathogenesis 
16h30  Inhibition of rabies virus replication by Micro-RNA   N.  Israsena  (CUHR, Thailand) 
16h40 Discussion 
17h00  Keynote speech: Rabies at the dawn of the 21st   H.  Koprowski  (TJU, USA) 
Century 
 
Wednesday, 30 May 2007 
09h00 - Session 5 / General conclusions and recommendations 
Chairperson: N. Belev (OIE) - Rapporteur: T. Müller (FLI, Germany) and A.R. Fooks (VLA, UK) 
10h00  Coffee break 
10h30  Report of the questionnaire on stray dog control  S. Kahn (OIE, France) 
10h40  Keynote speech: What have we achieved?  D. Briggs (VMC, USA) 
The way forward 
11h15  Announcement and video of the next conference 
11h30  Closing of the conference 
13h00  Press point 
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TOWARDS THE ELIMINATION OF RABIES IN EURASIA: OVERVIEW AND 
PERSPECTIVES 
J. Blancou  
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11, rue Descombes, 75 017 Paris, France 
After a short overview of the present and past epidemiological situation regarding animal and human 
rabies in Eurasia, the general characteristics of the disease are described in each vector.  
Three main rabies cycles are presently established in Eurasia: in dogs, in wild carnivores and in 
insectivorous bats. Because of the strong barrier that exists between species-adapted rabies viruses and 
various potential hosts, these cycles are quite independent. They are perceived in many countries in 
Eurasia not to have a significant impact on animal health or the rural economy in general: losses of dog 
(or cattle) are therefore also not priority animal health issue at the national level; wildlife rabies have 
been almost eliminated from western Eurasia by oral vaccination campaigns; and bats do not represent 
a real threat for a well informed public. 
Rabies is thus essentially a public health issue. Human rabies of canine origin has continued unabated 
since centuries in eastern Eurasia, despite the Pasteur treatment and subsequent improvements of 
rabies post-exposure prophylaxis, modalities and biological products. This as dog rabies, which is the 
main source of human contamination, remains practically uncontrolled. The Ministries of Health of all 
infected countries of Eurasia, should focus their attention on canine rabies first as it incurs endless 
expenses treating humans that have been exposed to dog bites. 
These Ministries should use the competences of Veterinary Services and all the other national bodies 
involved in dog rabies control, and contribute all necessary resources to support them to control this 
reservoir. This goal seems achievable in less than five years in a country, provided that cost-shared, 
well-planed and mass dog oral vaccination campaigns are organised and coordinated at regional and 
international levels. The conditions for the success of such campaigns are presented.  
______________ 
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The analysis of the present rabies situation in Western Europe is based on completed questionnaires 
from 16 countries. The questionnaire is focusing on the years 2005 and 2006. Additional information 
was obtained from the “Rabies Bulletin Europe”, and from OIE’s publication on “Historical perspective 
of Rabies in Europe and the Mediterranean Basin”. Rabies in domestic animals and wild carnivores has 
become very rare in Western Europe. Only Germany reports a fair number of rabid foxes for 2005. Bat 
rabies was observed in 4 countries. One imported human case was seen in the UK, while Germany 
reported 4 cases in transplant recipients. Wildlife vaccination campaigns were conducted by Austria, 
Germany and France. Reporting of human postexposure prophylaxis is inconsistent due the lack of 
information. Similarly, data on domestic animal rabies prophylaxis seem to be difficult to collect. 
_______________ 
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An overview of the rabies situation in the 19 countries of Central and Eastern Europe covering more 
than 2.5 million km2 is presented. A total of 6,500 cases of rabies were reported in this region in 
2005, 31% in domestic animals, and 69% in wild animals. Rabies was found in a limited number of 
dogs in 10 countries, and sporadically in 7 bats in 3 countries. The situation for the year 2006 was 
similar. In general, rabies cases in humans are very rare; however, two human rabies cases were 
reported in Byelorussia in 2006. Around 40,000 people receive post-exposure prophylaxis annually due 
to exposure with rabies suspect animals. The red fox (Vulpes vulpes) is the main vector and reservoir of 
rabies in Eastern Europe representing 50% of all rabies cases. The raccoon dog (Nyctereutes 
procyonoides) is another significant vector, mainly in the Baltics. Oral vaccination is used in varying 
degrees in 10 countries with promising results. Two countries are currently rabies free, and several 
others are close. An unfavorable situation remains mainly in the Baltics and nearby eastern countries, 
and also in some Balkan regions. Rabies as a notifiable disease in all countries studied. Those 
countries have implemented appropriate national legislation on rabies control as well as national 
reference laboratories. 
_______________ 
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Rabies is the most important zoonosis in Central Asian countries. In the years 2005 and 2006, a total 
of 615 animal rabies cases were reported of which 78%, 17% and 5% were found in dogs and cats, 
domestic animals and wildlife, respectively. Foxes accounted for 78% of all wildlife rabies cases. For 
the reporting period about 31 cases of human rabies were confirmed by laboratory testing. Eighty four 
and 16% of the cases dogs were due to contact with dogs and wildlife, respectively.  
Rabies is a notifiable disease in all central Asian countries and national legislations on animal rabies 
control and human rabies prevention are in place. Rabies data collation and reporting is established on 
a monthly and annual basis. Based on a rough estimate between 30 and 50% of the dog population are 
considered owned dogs, whereas 10-20% and 30-50% of dogs either having owners but run wild or are 
stray dogs. There is no information on the real stray dog population density and on stray dog control 
measures available. The issue of rabies control in wildlife is not considered yet.  
Rabies poses a serious problem for public and animal health despite existing national rabies control 
programs suggesting an urgent need for improvement. To make rabies control more effective in Central 
Asian countries it is necessary to adapt the national programs accordingly and to increase the overall 
vaccination coverage in dogs and cats. To tackle the rabies problem in wildlife oral vaccination of foxes 
might be a promising option. The worldwide experience of oral rabies vaccination, however, needs to 
result in an adequate vaccination strategy under the prevailing ecological and climatic conditions. 
_______________ 
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Rabies is a public health problem of significant importance in the majority of southern and eastern 
Mediterranean and Middle East countries. In some of them the number of deaths keeps on a 
considerable rate. The dog is the main source of human infection while cats constitute the second most 
important group of domestic animals followed by cattle, sheep, goat, camels, donkeys as well as wild 
animals. 
The number of reported human cases in these regions range from 800 to 1000 annually. Moreover, 
tens of thousands people need post-exposure prophylaxis in each country every year. Laboratory 
confirmation of rabies cases is not always performed. In most countries there is only one central 
laboratory for rabies diagnosis with trained staff while the diagnosis capability of district laboratories is 
still relatively poor and insufficient. 
Animal rabies control consists mainly on sporadic vaccination of dogs and cats, elimination of stray 
animals, health education of the pubic, etc. Unfortunately, mass vaccination of dogs is not 
implemented yet, because the effective vaccination coverage rate is not exactly known. Culling of stray 
dogs and other animals using both shooting and poisoning is still in place in certain countries, however, 
with either minimal or no effect on rabies transmission. 
Certain countries of the Middle East region, e.g. Saudi Arabia, Oman, Yemen, Israel, Iran and Turkey, 
are facing new problems due to emerging wildlife rabies. Red foxes (vulpes vulpes) and golden jackals 
(canis aureus) might play an important role. 
Coordinated actions should be undertaken by affected countries with the assistance of International 
Organizations, to confront the serious rabies public health and economic problems under suitable 
conditions according to the country.  
_______________ 
 
Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia”  
Paris (France), 27-30 May 2007  17 Abstracts  EPIDEMIOLOGICAL INFORMATION  Chairman: V. Caporale 
Session 1  RABIES IN EURASIA: REGIONAL REPORTS  Rapporteur: B. Dodet 
 
THE RABIES SITUATION IN FAR EAST ASIA 
Z.F. Fu 
Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA 
 
S
S
S
1
1
1
 
 
 
•
•
•
 
 
 
R
R
R
e
e
e
g
g
g
i
i
i
o
o
o
n
n
n
a
a
a
l
l
l
 
 
 
R
R
R
e
e
e
p
p
p
o
o
o
r
r
r
t
t
t
s
s
s
 
 
 
 
Aims/Objectives: This study was to evaluate human rabies epidemiology in Far East Asia.  
Materials and Methods: Questionnaires were sent by OIE to relevant countries and recent publications 
were reviewed to gather information as to rabies epidemiology in these countries. 
Results / Discussion / Conclusions: Mast of the human rabies in the world occurs in Far East Asia and 
more than 28,000 deaths has been reported each year, which represents more than 50% of all human 
rabies cases around the globe. There are only a few countries or regions from which no human rabies 
has been reported such as Japan, Singapore, South Korea, Hong Kong, and Taiwan. In many of these 
rabies endemic countries, the number of human rabies cases has not changed much during the past 
decade. The only country that has seen steady decline is Thailand and the number of cases has 
decreased from around 200 to about 20 cases per year. The most dramatic changes are observed in 
China. Human rabies cases decline from around 5,000 cases per year in the 1980s to about 160 in 
the middle of 1990s. However, these trends were reversed since then. A steady increase has been 
reported during the past 10 years with more than 3,200 cases reported in 2006. Although there are 
many factors that contribute to the epidemic or endemic nature of rabies in these countries, the single 
most important factor is the failure to immunize domestic dogs that transmit rabies to humans. 
However, dog vaccination is at or below 5%, which will not be able to stop the transmission from dogs 
to dogs, thus to humans. It is thus most important for these countries to initiate mass vaccination 
campaigns in dog populations in order to stop the occurrence of human rabies. 
_______________ 
  Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
18  Paris (France), 27-30 May 2007 Abstracts  RABIES PATHOGENESIS  Chairman: A.C. Jackson 
Session 2    Rapporteur: M. Lafon 
CYTOKINE EXPRESSION IN THE CNS AND PERIPHERY DURING INFECTION 
WITH RABIES 
N. Johnson
1, K.L. Mansfield
1, D. Hicks
1, A. Nunez
1, D. Healy
1, S.M. Brookes
1, C. Mckimmie
2,  
J.K. Fazakerley
2 & A.R. Fooks
1
 
S
S
S
2
2
2
 
 
 
•
•
•
 
 
 
P
P
P
a
a
a
t
t
t
h
h
h
o
o
o
g
g
g
e
e
e
n
n
n
e
e
e
s
s
s
i
i
i
s
s
s
 
 
 
 
1  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
2  Virology, Centre for Infectious Diseases, College of Medicine and Veterinary Medicine, University of Edinburgh, 
EH9 1QH 
Aims/Objectives: Rabies virus causes severe encephalitis that is invariably fatal for the victim. However, 
the contribution of the virus and the host to the damage of the Central Nervous System (CNS) is 
unclear. In order to investigate this we have studied the cytokine expression patterns within a murine 
model of rabies using a street isolate derived from a human case of disease. 
Materials and Methods: In the murine model, infection of the CNS progresses rapidly following 
inoculation in the periphery, and virus replication can be detected in the spinal cord, brain and salivary 
gland at 11 days post-infection (p.i.). Rabies virus (isolate RV61 and Challenge Virus Standard) were 
detected by end-point PCR and immunohistochemistry. Murine transcripts were detected by real-time 
reverse transcriptase PCR. 
Results / Discussion / Conclusions: By the time severe clinical symptoms have appeared at day 11 p.i., 
there is a large magnitude up-regulation in the brain of a range of inflammatory cytokines including IL-
6 and TNF-alpha, along with an up-regulation of TLR-3 and 2’-5’ OAS1. Transcription of certain 
chemokines (CCL5 and CXCL10) with chemotactic properties for T cells was also observed to increase. 
Furthermore there is an increase in the transcription of type-2 interferon (gamma) during the late 
stages of infection. However, this increase is not matched by the development of T cell infiltration into 
the brain and subsequent anti-viral responses that might prove deleterious to the host. Instead it seems 
that it is the actions of the virus that cause the loss of nervous function. This is in contrast to the 
observations made with a fixed strain of rabies virus, which shows distinct inflammatory changes within 
the CNS.  
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NEUROIMAGING, VIRUS AND CYTOKINE STUDIES IN RABIES INFECTED 
DOGS 
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1  Department of Radiology, Ramathibodi Hospital, Mahidol University 
2 
  Department of Medicine, Chulalongkorn University Hospital 
3
  Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand 
Objective: Furious and paralytic rabies differ in terms of clinical manifestations and sites of anatomical 
involvement. We studied whether there were specific patterns of magnetic resonance imaging (MRI), 
cytokine and virus distribution in rabies infected dogs of both clinical types. 
Methods: MRI of the brain and upper spinal cord were performed in 2 furious and 2 paralytic dogs 
during early stage. Rabies virus RNA and mRNA of 19 cytokines were determined at each of 12 brain 
regions of early (2 furious, 2 paralytic) and late (one each) stage rabid dogs. 
Results: Two different MR imaging patterns were evident. Abnormal hypersignal T2 changes were found 
at hippocampus, hypothalamus, brainstem and spinal cord in 2 paralytic dogs. More widespread 
changes but of less intensity were noted in 2 furious dogs. During early stage, virus RNA was found 
mainly in the midline structures in all but one furious dog that had virus RNA in most regions. IL-1 
beta (2/2) and interferon-gamma (2/2) mRNAs were found at most regions starting at the early stage 
only in paralytic dogs. During early stage of both clinical types, TNF-alpha (3/4), TGF-beta (4/4), IL-12 
(3/4) and -18 mRNAs (4/4) were found in the midline structures.  
Conclusions: Two distinct patterns of MRI abnormalities were found in furious and paralytic rabies. 
Rabies virus RNA was distributed mainly in the midline structures. This does not explain limbic 
symptoms. It remains to be determined whether cytokine responses at particular regions influence the 
development of clinical aggression and extent of virus distribution in the brain. 
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ROLE OF CALCITONIN GENE-RELATED PEPTIDE (CGRP) IN THE 
PATHOGENESIS OF RABIES 
E. Weihe
1, M. Bette
1, M.A.R. Preuss
1, 2, M. Faber
2, M.K. Schäfer
1, M.J. Schnell
2 & B. Dietzschold
2
1  Inst. of Anatomy, Dept. of Mol. Neuroscience, Philipps Univ. Marburg, Germany 
2  Dept. of Microbiology & Immunology, Thomas Jefferson Univ., Philadelphia 
Here we test whether rabies virus (RV) infection enhances CNS expression of CGRP and other 
immunomodulatory neuropeptides to escape immune responses. To investigate the effect of RV 
infection on cerebral CGRP in relation to microglial and inflammatory responses, we studied the effect 
of TNFa using recombinant RVs that contained either an active (SPBN-TNFa(+)) or an inactive (SPBN-
TNFa(-)) TNFa gene.  
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While RV infection did not significantly affect the expression of most neuropetides, it caused a strong 
upregulation of CGRP in non-infected cortical and hippocampal neurons. Infection with SPBN-TNFa(+) 
resulted in reduced upregulation of CGRP as compared to that seen in SPBN-TNFa(-)-infected brains. 
The induction of the invariant chain of MHC-II, the activation of microglia, and the infiltration of 
inflammatory cells was strongly enhanced in SPBN-TNFa(+)- as compared to SPBN-TNFa(-)-infected 
brains. Mice infected with SPBN-TNFa(+) showed decreased virus spread compared to mice infected 
with SPBN-TNFa(-). While none of the SPBN-TNFa(+)-infected mice died, 80% of mice infected with 
SPBN-TNFa(-) succumbed to the infection.  
Given the known inhibitory effect of CGRP on antigen presentation, we conclude that CGRP induction 
in brain after RV infection represents a potential mechanism by which RV escapes immune detection. 
The protective activity of TNFa may be due to reduced upregulation of CGRP with concomitant 
enhancement of CNS inflammation. This in turn, might prevent the escape of RV from innate and 
adaptive immune responses. Thus, the use of CGRP antagonists to unleash the inhibition of antigen 
presentation during RV infection could represent a useful strategy in post-exposure prophylaxis of 
rabies.  
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PATHOGENIC AND ATTENUATED RABIES VIRUSES INDUCE DIFFERENTIAL 
HOST PROTEIN EXPRESSION IN THE CENTRAL NERVOUS SYSTEM: 
IMPLICATION OF NEURONAL DYSFUNCTION 
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Z. F. Fu 
Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA 
Aims/Objectives: This study was to understand how rabies virus (RV) infection results in neuronal 
dysfunction. 
Materials and Methods: We employed proteomics technology to profile host responses to RV infection in 
the mouse model. 
Results / Discussion / Conclusions: In mice infected with pathogenic RV, the expression of proteins 
involved in ion homeostasis was altered. H+ ATPase and Na+/K+ ATPase were up-regulated while Ca2+ 
ATPase was down-regulated, which resulted in reduction of the intracellular Na+ and Ca2+ 
concentrations. Furthermore, infection with pathogenic RV resulted in down-regulation of SNAREs such 
as￿-SNAP, syntaxin, and pallidin, all of which are involved in docking and fusion of synaptic vesicles to 
and with presynaptic membrane. As a consequence, accumulation of synaptic vesicles was observed in 
the presynaptic membrane in mice infected with pathogenic RV. On the other hand, attenuated RV did 
not induce changes in the expression of these proteins. Together, our data demonstrate that infection 
with pathogenic RV results in alteration of host protein expression, particularly those involved in ion 
homeostasis and docking and fusion of synaptic vesicles to presynaptic membrane, which may provide 
the structural and metabolic basis by which RV infection causes neuronal dysfunction.  
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DOMINANCE OF A NON-PATHOGENIC OVER A PATHOGENIC G PROTEIN 
GENE IN DEFINING THE PATHOGENICITY OF A RABIES VIRUS 
B. Dietzschold 
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA 
The non-pathogenic phenotype of the rabies vaccine virus SPBNGAN is determined by a G protein 
designated as GAN that has an Arg → Glu exchange at position333. We have recently shown that after 
several passages of SPBNGAN in newborn mice an Asn → Lys mutation occurred at position 194 of 
GAN resulting in GAK, which was associated with a reversion to the pathogenic phenotype. To 
investigate whether the presence of two GAN genes within the genome of the nonpathogenic double G 
RV variant SPBNGAN-GAN increases or decreases the probability for reversion to the pathogenic 
phenotype, double G RVvariants were constructed that contain both, the non-pathogenic GAN and the 
pathogenic GAK gene (SPBNGAN-GAK or SPBNGAK-GAN). Additionally, we constructed an RV 
containing two pathogenic RV G genes (SPBNGAK-GAK). While SPBNGAK-GAK was pathogenic, 
SPBNGAN-GAK was completely non-pathogenic and the pathogenicity of SPBNGAK-GAN was strongly 
reduced. Furthermore, virus loads in SPBNGAN-GAK-and SPBNGAK-GAN-infected brains were 
significantly lower than those detected in SPBNGAK-GAK-infected brains, indicating that the non-
pathogenic phenotype determined by GAN is dominant over the pathogenic phenotype associated with 
GAK. Virus production and viral RNA synthesis were markedly higher in SPBNGAN-, SPBNGAK-GAN- 
and SPBNGAN-GAK-infected NA cells than in SPBNGAK- and SPBNGAK-GAK-infected NA cells, 
suggesting that the dominance of GAN over GAK is controlled at the level of viral RNA synthesis. These 
data not only confirm the concept that the pathogenicity of an RV correlates inversely with its capacity 
to replicate in vitro but also support the conclusion that a recombinant RV carrying two identical GAN 
genes bears a lower risk of a reversion to the pathogenic phenotype than an RV carrying only a single 
GAN gene.  
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2  Department of Primary Industries and Fisheries, Brisbane, Queensland, Australia 
3
  Kansas State University, Manhattan, Kansas, USA 
4
  Agence Française de Sécurité Sanitaire des Aliments, Malzéville, France 
5
  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
6
  Queen Saovabha Memorial Institute, Bangkok, Thailand 
7  World Health Organization, Geneva, Switzerland 
8  Friedrich-Loeffler-Institut, Federal research Institute for Animal Health, Wusterhausen, Germany 
9  University of Pretoria, Pretoria, South Africa 
10 Pan American Health Organization, Washington, D.C., USA 
11Institute Pasteur, Paris, France 
12 Canadian Food Inspection Agency, Nepean, Ontario, Canada 
Rabies is the most significant viral zoonosis at large today. From public health, veterinary and 
economic standpoints, the disease requires renewed consideration in relationship to eradication. Given 
wildlife involvement on all major continents, and in particular the evolutionary and ecological role of 
bats as reservoirs, rabies is not a candidate for true eradication at this time, from a classical definition. 
Nevertheless, the opportunity for shared scientific expertise, multi-disciplinary leadership, technology 
transfer, creative vision, and political willingness, offers the promise of significant outcome-oriented 
collaborations in an unprecedented fashion during the 21st century. Laboratory-based surveillance, 
combined with active health education and enhanced public awareness, and the strategic utilization of 
potent inexpensive vaccines, are basic requirements for effective rabies prevention and control. Human 
rabies can be eradicated by eliminating exposures, expanding primary vaccination for those at risk, and 
proper, timely application of modern postexposure prophylaxis. Canine rabies transmission can be 
eliminated, as documented in developed and developing countries, especially as exemplified 
throughout Latin America. Wildlife rabies can be controlled significantly, and among certain carnivore 
populations suppressed, as demonstrated by regional elimination over major portions of Europe and 
North America. Rather than concentrate random initiatives concomitantly on a worldwide basis, 
coordinated steps should encompass selection of areas or regions with the ideal biological, social, and 
political underpinnings to maximize the greatest probability for success as exemplary showcases for 
gradual expansion. Ultimately, major financial commitment and serious long term partnering with 
interested member countries and organizations are perquisites for appreciable recognition of global 
rabies eradication goals. 
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1  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
2
  Pasteur Institute Novi Sad, Yugoslavia 
3  Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China 
4  Unité de la Rage, Institut Pasteur, Paris, France 
5  Federal Research Centre for Virus Diseases of Animals, D16868 Wusterhausen, Germany 
Advances in molecular epidemiological methods over the past 15 years have resulted in an increase in 
genetic data on lyssaviruses circulating in a range of host species worldwide. The molecular diversity of 
classical rabies viruses (Genotype 1, RABV) has been studied at the global level and reference has been 
made to the existence of a number of European strains in a range of mammalian species. They are 
believed to be clustered within a ‘Cosmopolitan Lineage’ having ancestral roots in Europe in the 17th 
century before its widespread dispersal to Asia, Africa and the Americas as a result of European 
exploration and colonization. To further investigate the existence of such a lineage in Eastern Europe 
and Asia, a molecular epidemiological review of new and existing data was undertaken for Eurasian 
RABV isolates. A phylogenetic study has been performed on a unique panel of viruses from the Former 
Republic of Yugoslavia, isolated from a wide range of hosts over a 30 year period. A number of 
divergent strains have been identified in this region. In contrast, when we performed targeted 
surveillance of stray dogs in the poor socioeconomic areas of three Chinese provinces (Sichuan, Hunan 
and Guangdong) and within Tianjin City, very little genetic diversity was identified. In addition, we will 
report on a targeted surveillance programme of insectivorous bats in the Guangdong, Guandxi, Yunan 
and Hainan provinces of China, provoked by the emergence of the new bat lyssaviruses (Aravan, Irkut, 
Khujand and West Caucasian Bat Virus) in Eurasia.  
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1  Kimron Veterinary Institute, Bet Dagan, 50250, Israel 
2  The University of Edinburgh, Edinburgh, EH9 1QH, UK 
3  Etlik Central Veterinary Controls and Research Institute, Etlik, Ankara, Turkey 
4  Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA 
Rabies is endemic in the Middle East, however so far only Israel has implemented an oral rabies 
vaccination (ORV) control program. Molecular analysis of a 328 bp long fragment of the rabies virus 
(RABV) nucleoprotein (N) gene was used to identify variants of rabies viruses obtained in a previous 
wild life control program. We identified rabies virus isolates from years 1993-1998 into 4 clades (I-IV) 
occurring in 4 geographical regions of Israel. 
Objectives: To conduct ORV and rabies surveillance along Israeli borders. 
Materials and Methods: We analysed 90 Israeli and 28 RABV isolated in border regions from 
neighbouring countries; seven from the Jordan border region, three from Lebanon border region, and 18 
from Syrian border region. We also analysed three RABV isolates from Egypt, six from Jordan and seven 
from Turkey. 
Results: An antigenic and phylogenetic analysis of the Middle Eastern RABV isolates was conducted. 
Also, the chronological evolution of the RABV variants was estimated using molecular clock. The 
phylogenetic analysis of the rabies virus sequences revealed four new genomic clades, with clades V, VI 
and VII occurring in the Middle East and calde Africa 4 circulating in North Africa. The molecular clock 
application indicated that the current diversity of canine RABV variants from the Middle East emerged 
at about the same time (~1870) as in Europe, following their divergence from established lineages in 
Africa and Asia.  
Discussions and Conclusions: There is evidence that the RABV circulating in the Middle East belong to 
novel canine clades V, VI, VII, which appeared on the borders and invaded Israel from Jordan and Syria. 
A strict surveillance is required along borders of countries where ORV control program is performed to 
avoid further spread of these RABV variants. 
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RABIES IN SOUTH ASIA - EPIDEMIOLOGICAL INVESTIGATION 
C.K.Singh
1 & B.S. Sandhu
2
1  Veterinary Pathologist 
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2  Assistant Professor, Department of Veterinary Pathology, College of Veterinary Science, Guru Angad Dev 
Veterinary and Animal Sciences University, Ludhiana, Punjab, India 
A five year study was conducted in northern India to investigate epidemiological aspects of rabies in 
different animal species. Brain tissues were collected from a total of 384 rabies suspect animals 
including 231 dogs, 79 buffaloes, 46 cows and 28 wild species. Out of the 384 suspected cases, 
55.98% were positive for rabies as shown by direct fluorescent antibody test (FAT). Among the various 
species of animals, the maximum rabies cases were found in dogs (59.53 %) followed by buffaloes 
(20.46%), cows (13.48%) and wild animals (6.51%). Increased incidence was observed during 
January to April and during August to November. Analysis of the age and sex of different species 
revealed that adult male dogs (39%) and adult female bovines were more affected by rabies.  
Concerning the major clinical presentations 30% of the rabid animals demonstrated the paralytic form 
of rabies whereas 61 % of the rabid dogs showed the fuious form of rabies with aggressivness as the 
predominant clicial symptom. There was proven evidence that the majority of rabid dogs (61%) had 
bitten humans or other animals. In buffaloes and cows, anorexia, salivation and bawling were the main 
clinical symptoms. Histopathological demonstration of Negri bodies was less sensitive than FAT in 
detecting rabies in both domestic and wild animals. In 27% and 24% of the cases owners were able to 
identify rabies related clinical symptoms in buffaloes and cows, respectively. In contrast, 47% of dog 
rabies cases were discerned by dog owners due to obvious clinical signs. The accumulated history 
records revealed that 78% of owned rabid dogs were not prophylactically vaccinated against rabies. 
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1  Queen Saovabha Memorial Institute (WHO Collaborating Center for Research on Rabies), Thai Red Cross Society, 
Bangkok, Thailand 
2  Veterinary Public Health Division, Health Department, Bangkok Metropolitan Administration, Bangkok, Thailand 
In Thailand, rabies incidence is highest in stray dogs. Dog bite-related rabies cases account for 70% to 
95% of the reported human rabies deaths in Thailand. The incidence of dog bites is highest in the 
central part of the country, e.g. the Bangkok metropolis where an estimated 900,000 dogs live. 
Approximately 17% of the estimated dog population is considered ownerless or stray dogs. In a 
previous epidemiologic survey it could be shown that no less than 5 canine rabies virus variants are 
circulating among dogs of the Bangkok metropolis. According to WHO recommendations, at least 70% 
of the dog population has to be continuously vaccinated to control rabies effectively. However, little is 
known about the vaccination status in stray dogs. The objective of our study was to investigate the 
rabies incidence and rabies antibody prevalences among stray dogs in Bangkok. Both saliva and serum 
samples from a total of 3,314 stray dogs captured between 12/2003 and 6/2004 were collected and 
subsequently tested for the presence of rabies virus and rabies specific antibodies, respectively. Rabies 
virus antigen could be detected in a one 2-year-old female dog by latex agglutination test and was also 
confirmed by reverse transcription-polymerase chain reaction. The overall antibody seroprevalence as 
detected by enzyme-linked immunosorbent assay was 62% (95% CI: 54, 70%). Antibody 
seroprevalence was higher in dogs captured within central Bangkok (86% of 1208 dogs captured) than 
in dogs captured in the outskirts of the greater metropolitan area (49% of 2106 dogs captured). 
Provided the sample size of stray dogs is representative, the results obtained would indicate that the 
seroprevalence achieved from previous vaccination campaigns is too low to protect both the dog and 
human population. 
_______________ 
  Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
28  Paris (France), 27-30 May 2007 Abstracts  RABIES PREVENTION AND CONTROL STRATEGIES  Chairman: F. Cliquet 
Session 3  Rabies control in dogs  Rapporteur: B.A. Yakobson 
PREFERENCE FOR COMMERCIALLY PRODUCED ORAL RABIES BAITS BY 
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1  USDA/APHIS/Wildlife Services, Phoenix, Arizona, USA 
2  Navajo Nation Veterinary Program, Chinle, Arizona, USA
3
  USDA/APHIS/Wildlife Services, Concord, New Hampshire, USA 
4  Centers for Disease Control and Prevention, Atlanta, Georgia, USA 
5  USDA/APHIS/Wildlife Services, Ft. Collins, Colorado, USA 
Domestic dogs are the leading vector for rabies throughout the world. On United States Indian 
Reservations rabies vaccinations for dogs may be as low as 5 to 20%. At the aforementioned rates, it 
would be nearly impossible to break the rabies cycle through vaccination of dogs. The US Department 
of Agriculture, Animal and Plant Health Inspection Service, Wildlife Services and the Centers for 
Disease Control and Prevention were invited by the Navajo and Hopi Nations to determine the 
acceptance of commercially available rabies baits by tribal dogs. During 2003 and 2004, we have 
offered Artemis Ontario Slims, Merial raccoon baits, Merial gray fox baits and Merial fish meal coated 
sachets. Baits were hand tossed to each individual animal. We recorded whether the animal ignored the 
bait, swallowed the bait whole, chewed and discarded the bait without puncturing the placebo packet, 
chewed and punctured the placebo packet and discarded the bait, and chewed and punctured the 
placebo packet and swallowed the contents. Preference among the baits from least favorable to most 
favorable were Artemis Ontario Slims < Merial raccoon baits < Merial gray fox baits < Merial coated 
sachets. For 2003 and 2004, we had an acceptance rate of 78% for coated sachets. During 2005 and 
2006, we used the Merial fish meal coated sachets with Raboral V-RG in Chinle and Window Rock, 
respectively. Acceptance by feral dogs was 85% acceptance rate in 2005 and a 74% acceptance rate 
in 2006. Coated sachets are a strong candidate for ORV in dogs. 
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B.A. Yakobson
1, R. King
2, N. Sheihat
1 & D. David
1 
1  Kimron Veterinary Institute, Bet Dagan, Israel 
2  Nature & park Authority, Jerusalem, Israel 
Since 1956, red foxes (Vulpes vulpes) and golden jackals (Canis aureus) have been the primary vectors 
maintaining wildlife rabies in Israel. Oral rabies vaccination of wild canids initiated in 1998 resulted in 
near-elimination of the disease in wildlife by 2005. During 2005 and 2006, an outbreak of rabies was 
observed in stray dogs in the vaccination area of the Golan Heights, with no cases in foxes or jackals. 
Epidemiological investigations showed that the infected dogs were from territories across the border. 
This was confirmed by molecular analysis, which showed that the rabies virus (RABV) was different 
from RABV isolates endemic to this area. The objective of this study was to determine bait acceptance 
and feasibility of oral rabies vaccination in semi-wild shepherd dogs. Coated sachets and fishmeal 
polymer baits of Raboral V-RG (Merial, USA) were tested in five different test zones. Both formats were 
hand-fed to individual dogs and to animals belonging to packs. Bait uptake and consumption were 
observed for each dog. Uptake of either bait format was >90%. Vaccine delivery problems were 
observed in dogs belonging to packs; dominant animals ate multiple baits and in competitive situations 
dogs gulped the bait on the whole. Because of the uncertainty associated with the oral vaccination of 
dogs other methods were needed to control this outbreak: stray dogs were removed and herd dogs were 
vaccinated parenterally. This study showed that oral rabies vaccination of dogs in packs using vaccine 
baits designed for wildlife would not be effective. Perhaps the search for different baits or for soltutions 
to circumvent competition within the dog pack can help to make this approach feasible. 
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S.F. Zhang
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2, F. Zhang
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1  Laboratory of Epidemiology, Veterinary Institute, Academy of Military Medical Science, 1068 Qinglong Road, 
Changchun 130062, P.R.China 
2  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
Rabies cause about 55 000 human deaths worldwide each year, up to 98% of the cases were caused 
by exposure to rabid dogs. Prevention of dog rabies would be the most effective way to stop rabies 
transmission to humans. However, vaccinating stray dogs in urban and rural areas using conventional 
vaccines is always difficult and is not cost-effective for use in China. In this paper, we utilized a 
recombinant rabies vaccine, in which the canine adenovirus type-2 served as a live vector and the 
rabies virus glycoprotein as the protective antigen, performed a non-parenteral trial in dogs. This 
vaccine was orally or intranasally administrated once to 136 dogs in solution form (46) with 1×108.5 
PFU or in a specially designed bait (90) with 3×108.5 PFU recombinant adenovirus. About 87.5% 
(119/136) of the immunized dogs developed neutralizing antibodies. The protective immune response 
against rabies in dogs was detectable at 2-3 weeks after administration, reaching a peak by 5-6 weeks. 
Among the seroconverted animals, 90.8% (108/119) elicited a neutralizing antibody response for over 
24 months. The antibody titre during the two years was above 0.5IU/ml while showing a gradual but 
slow decline from 6 weeks after vaccination. In a challenge experiment of 10 dogs 2 years after the 
vaccination with 60,000 mouses LD50 of CVS-24, all of the dogs survived. It is hoped to further 
improve the bait design for commercial production. Nevertheless, the results demonstrated that the 
recombinant vaccine and its bait were useful for oral immunization of dogs. 
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1  HSADL-High Security Animal Disease Laboratory, Indian Veterinary Research Institute, Anand Nagar, Bhopal 
462021, Madhya Pradesh, India 
2  Petswill, Kesar Complex, Malhar Road, Gurudev Nagar, Ludhiana, Punjab, India 
3  AFSSA, National Research Laboratory on Rabies and Wildlife Diseases, WHO Collaborating Centre for Research 
and Management in Zoonoses Control, OIE Reference Laboratory on Rabies, EU Reference Institute for Rabies 
Serology, Technopole Agricole et Vétérinaire, BP 40009, Malzéville, France 
4  VIRBAC Laboratories, B.P. 27, 06511 Carros Cedex, France 
5  Conseils en Pharmacie et Biologie, Santé, 69110 Sainte Foy les Lyon, France 
6  AFSSA, Small Ruminants and Bee Research Laboratory, 105 route des Chappes, BP 111, F-06902 Sophia 
Antipolis Cedex, France 
7  World Health Organization, Department of Communicable Diseases, 1211 Geneva, Switzerland 
In India, about 20,000 people die of rabies every year. The dog is the main reservoir and vector of the 
disease. A pilot rabies control programme has been launched in 5 Indian federal states in February 
2007. This initiative is led by the Animal Welfare Board of India (AWBI) federating many animal 
welfare organizations and the Ministry of Agriculture. It aims at creating a “Rabies Free India”.  
The programme combines parenteral vaccination of accessible owned dogs, stray dog population, 
spaying/neutering followed by parenteral vaccination and oral vaccination of unaccessible dogs. The 
freeze-dried vaccine SAG2 including the bait casing has recently been registered in India following 
successful evaluation of vaccine-bait safety and efficacy (by survival after virulent challenge) in captive 
Indian stray dogs in the Bhopal high security laboratory. Furthermore, bait acceptance was tested under 
both experimental and field conditions. Results of the experimental studies will be presented, which 
finally led to registration and field use of SAG2 baits in India. Furthermore, the AWBI strategy for 
rabies control and elimination will be discussed. 
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Rabies in dogs was unknown in the Americas before the arrival of the Spanish ‘conquistadores’. Until 
the middle 1980s rabies in animals and, in turn, in humans, changed little from year to year, when the 
number of canine vaccinations reported annually rarely reached one million. In Mexico, the national 
rabies control program using parenteral mass vaccination of dogs started in 1990 with a about 7 
million dogs vaccinated in the same year. The number of vaccinated dogs exceeded 10 and 15 million 
in 1995 and 2005, respectively. Modern cell culture based inactivated rabies virus vaccines were used. 
A key factor for the success of the dog rabies control program was the supply of potent canine rabies 
vaccines. Between 1990 and 2005 more than 150 million vaccine doses from 300 lots were 
administered. Each lot was tested for potency prior to use in the field. The required minimum content 
of rabies virus antigen of vaccines was 2 I.U according to WHO. Testing revealed antigen contents 
ranging from 3.28 to 5.59 IU. As a result of the mass dog vaccination campaigns human rabies cases 
due to dog-mediated rabies decreased from 60 in 1990 to 0 in 2000. The number of rabies in dogs 
decreased from 3,049 cases in 1990 to 70 cases last year. 
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1
  Rødkildevej 23, DK-4780 Stege, Denmark 
2
  Danish Meat Association, Vinkelvej 11, DK-8620 Kjellerup, Denmark 
3  Department of Virology, National Veterinary Institute, 751 89 Uppsala, Sweden 
4  AFSSA Nancy, Domaine de Pixérécourt, F-54220 Malzeville, France 
5  Institute of Microbiology and Parasitology, University of Ljubljana, Gerbi va 60, SI-1115 Ljubljana, Slovenia 
6  European Food Safety Authority, Panel on Animal Health and Welfare, Largo Natale Palli 5/A, I 43100 Parma, 
Italy 
7  National Veterinary School of Alfort, Avenue du Général de Gaulle, 7, 94704 Maisons Alfort, France 
In response to a request of the Commission of the European Union (EU) the European Food Safety 
Agency (EFSA) has carried out a quantitative assessment of the risk of rabies introduction into the UK, 
Ireland, Sweden, and Malta as a possible result of movements of pets incubating rabies at the time of 
movement.  
The risk that a pet is incubating rabies at the time of first vaccination is equal to the prevalence of 
rabies-incubating pets in the population of origin. Despite induction of immunity by vaccination 
animals already incubating rabies will still develop clinical disease as a function of time after 
vaccination (termed type A risk). Waiting time reduces this risk.  
A small percentage of animals may not be protected after single-shot primary vaccination and hence, 
may become infected after vaccination. The risk of becoming infected after the first vaccination 
(termed type B risk) depends on the prevalence and efficiency of vaccination. Serological testing can 
be used to identify non-immune pets and will therefore reduce this risk accordingly. Type A and B risk 
were modelled as a function of waiting time after vaccination and fitted to a non-linear model 
incorporating test specificity and vaccination efficiency. 
Within the EU, the prevalence and hence the type A risk is so low, that for most countries the risk is 
negligible. However, for some countries the risk is non-negligible. In this case inclusion of a waiting 
time is necessary to reduce this risk. Here, serological testing is appropriate, because type B risk 
becomes relatively more important as type A risk is reduced with extended waiting times (over 100 
days). 
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1
  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
2
  Federal Research Centre for Virus Diseases of Animals, D-16868 Wusterhausen, Germany 
3  Impfstoffwerk Dessau – Tornau GmbH, Rosslau, Germany 
4  Etlik Central Veterinary Control and Research Institute, Etlik, Ankara, Turkey 
5  Institute for Diagnosis and Animal Health, Doctor Staicovici Street no. 63, District 5 050557, Bucharest, 
Romania 
6  National Diagnostic and Research Veterinary Institute, 15A P.Slaiveikov Blvd, BG-1606, Sofia, Bulgaria 
7  Department of infectious diseases, Veterinary faculty, University of Sarajevo, Sarajevo, Bosnia and Hercegovina 
8  Veterinary Instiute of the Republik of Srpska, Banjy Luka, Bosnia and Hercegovina 
Aims/Objectives: Rabies remains endemic within a number of countries in southeast Europe including 
Romania, Bulgaria and Turkey. With the probable expansion of the European Union eastwards it is 
likely that rabies elimination programs will be increased to reduce the burden of this disease in new 
accession countries. A clear understanding of the epidemiology of the virus in this area of Europe is 
vital before such programs are introduced. With the exception of Turkey, the red fox (Vulpes vulpes) is 
the principal disease reservoir in this region. However, cases of rabies in the dog (Canis familiaris) are 
regularly reported. This study summarises the current rabies situation in southeast Europe and 
demonstrates the phylogenetic relationships between the viruses in a number of the countries within 
the region.  
Materials and Methods: Rabies virus RNA was extracted from original samples and a fragment of the 
nucleoprotein gene amplified by reverse-transcriptase PCR. Automated sequencing was used to derive 
nucleoprotein gene sequences and these were used to prepare a molecular phylogeny of rabies viruses 
in southeast Europe. 
Results / Discussion / Conclusions: In Bulgaria, the dog is the main vector bringing rabies into contact 
with humans and livestock. However, other species also act as reservoirs for the disease, complicating 
the development of elimination strategies. The fox is the principal reservoir species of rabies in 
Romania although cases in dogs are regularly reported. Despite a gradual decline in dog rabies, urban 
pockets of the disease remain in many regions of Turkey. Furthermore, there is some evidence that the 
fox has been a significant vector for rabies and may be responsible for increases in rabies in cattle in 
the Aegean region of the country. Throughout the region there is evidence for cross-border movement of 
rabies by both wildlife and canine vectors. 
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  Irkutsk State Medical University, Russia 
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  Center of Infectious Diseases with Natural Foci, Ulaanbaatar, Mongolia 
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3  Center for Diseases Control and Prevention, Atlanta, USA 
The presence of rabies in Mongolia is associated with its characteristic landscape, e.g. the steppes and 
forest-steppes, known as the Mongolian steppes. Main reservoirs of rabies virus (RABV) are the red fox, 
corsac fox and wolf. Fox rabies has been reported in Mongolia since the early 1960s. Eleven human 
rabies cases were reported during 1994-2004, approximately one case per year resembling about 0.4 
cases per one million inhabitants. Of the human rabies death 5 persons died after wolf bites, 2 people 
due to exposured to foxes, and 4 after dog bites. Children of cattle-breeders aged 4-7 years comprised 
about 50% of the human rabies cases. Biting attacks from herding dogs represent the main cause for 
post-exposure prophylaxis (PEP) in Mongolia with most people subjected to PEP in rural areas difficult 
to assess. During 1996-2004, a tatol of 1273 rabid animals were reported (about 140 cases per year). 
More than 80% of all reported cases occured in cattle. The rabies epizootic is cyclic, with 10 to 12 
year periods. In the years 2000 to 2002 a major rabies outbreak occurred in the north-western part of 
the country.  
The Mongolian steppes extend to the Chita region of Russia, the autonomous Republics of Buryatia, 
Tyva and Altai. Four RABV isolates from the central part of Mongolia were sequenced and compared 
with available isolates from Russia, Kazakhstan and China. The isolates from Mongolia all belonged to 
the “steppe” phylogenetic clade, which includes viruses circulating in vast steppe territories ranging 
from south-eastern Europe to Tyva, West Siberia and Kazakhstan. In contrast, RABV isolates from 
Mongolian-type steppes in Chita region of Russia (East Siberia) belong to the eastern group of arctic-
like viruses. Further research on characterisation of RABV from Mongolia is needed to confirm these 
findings. 
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Rabies is endemic in Iran. It is the most important zoonostic disease in the country. Based on studies 
conducted during the past decades there is evidence that the main reservoir for rabies are wolves.  
Rabies incidence in man and animals is increasing each year. In 2006, more than 130,000 people 
received post-exposure prophylaxis. Similar figures apply for preventive vaccination in animals.  
Offical data suggest that the majority of human exposures are due to bitings episodes caused by dogs. 
However, our investigations showed that mainly wolves are the responsible animal for rabies 
transmission to humans. Because of the potential feasibility of oral rabies vaccination, we proposed a 
pilot study to evaluate the use of an oral rabies vaccine for vaccination of wildlife to control rabies in 
Iran. 
Aims and objectives: To evaluate the possibility to control rabies in Iran using oral vaccination of wolves 
and to evaluate the immune reponse to oral rabies vaccine among wolves. 
Materials and Methods: Twenty wolves were experientally vaccinated using an oral rabies virus vaccine. 
Prior to vaccination the health status of each animal was examined by veterinarians. For the application 
of the oral rabies vaccine the animals were anaesthetised using tranquillizers. Also, a blood sample was 
taken to show the animals to be sero-negative for rabies prior to vaccination. One month after 
vaccination a second blood sample will be collected and tested for the presence of virusneutralising 
antibodies using the rapid fluorescent focus inhibition tests (RFFIT). 
This results obtained in this pilot study will be presented and discussed. Also, conclusions concerning 
the use of ORV under Iranian conditions will be drawn. 
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2  Finnish Game and Fisheries Research Institute, Turku Game and Fisheries Research, Itäinen Pitkäkatu 3 A, FI-
20520 Turku, Finland 
3  Kunnaantie 18 C 12, FI-01370 Vantaa, Finland 
Aims/Objectives: Raccoon dogs are seen as a new host for fox rabies in Europe. Disease spread in a 
community of species can change the epidemiology and require new disease control strategies. This 
study assesses the risk and strength of a rabies outbreak, introduced to a community of foxes and 
raccoon dogs in Southern Finland. 
Materials and Methods: Epidemiology is simulated with a two-species model, based on approaches for 
rabies in foxes and parameterised from recently published data on raccoon dog and fox ecology in 
North-east Europe. Risk of rabies establishment, strength of disease and temporal dynamics of the 
epidemics were investigated. 
Results / Discussion / Conclusions: Results show that rabies would not spread in a single species, when 
population densities are low, as in Finland. However persistent epidemics are very likely in the species’ 
community. Threshold density for the system of combined species reduces non-linearly, compared to 
thresholds of each of the species. Strength of a persistent disease depends on population density of 
both species; at high territory density raccoon dogs become the driving force. Even at low densities, the 
model predicts about twice as many infected raccoon dogs as foxes. Another behavioural factor that 
influences rabies epidemiology is raccoon dog hibernation, which may alter with climate change. 
Invasive raccoon dogs increase risk of rabies epizootics, especially in association with red foxes. The 
changed dynamics of epidemics in the community might require modification of control strategies. 
Assessing potential strategies should be the next step towards managing this new risk. 
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2  United States Department of Agriculture, Animal and Plant Heath Inspection Service, Wildlife Services, Concord, 
NH 03301 USA 
3
  Poxvirus and Rabies Section, Centers for Disease Control and Prevention, Atlanta, GA 30333 USA 
4  United States Department of Agriculture, Animal and Plant Heath Inspection Service, Wildlife Services, 
Washington, DC 20250 USA 
Translocation has been successfully used by wildlife professionals to: enhance or reintroduce 
populations of rare or locally extirpated wildlife, provide hunting or wildlife viewing opportunities, farm 
wild game, and to reduce local human-wildlife conflicts. Translocations of wildlife in the U.S. are 
estimated in the hundreds of thousands of animals each year. Accidental and intentional translocations 
may have multiple unintended negative consequences, including increased stress and mortality of 
relocated animals, as well as negative impacts on resident animals at release sites; increased conflicts 
with human interests; and the spread of diseases. Many wildlife professionals now question the need 
for translocation in light of the need to contain or eliminate high profile, economically important 
wildlife diseases such as chronic wasting disease, bovine tuberculosis and rabies. Moreover, 
translocation may jeopardize international wildlife disease management initiatives to control rabies in 
raccoons, coyotes and foxes in North America. Incidents where specific variants (Texas gray fox, canine 
variant in coyotes, and raccoon) have been moved well beyond their current range, including emergence 
of raccoon rabies from translocations, will be compared for their relative socioeconomic and ecologic 
impacts. The pervasiveness of translocation in the U.S. is reflected in part by the sale of nearly 1 
million live traps annually. We review the substantial challenge (legal and social dimensions) of 
attempting to curtail translocation, while recognizing that it logically deserves serious attention in 
conjunction with ORV as the movement of infected animals could jeopardize sizeable commitments of 
resources and personnel, ORV programs, and the future of ORV in the U.S. 
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SYLVATIC RABIES IN RUSSIA WITH SPECIAL ATTENTION TO PERSPECTIVES 
OF ORAL VACCINATION OF WILD CARNIVORES 
A.D. Botvinkin
1, D.V. Bankovsky
2 & G.A. Safonov
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1  Irkutsk State Medical University, 664003, Irkutsk, Russia 
2  Pokrov Plan of Biologics, 601125, Volginsky, Vladimir region, Russia 
An overview of rabies control strategies in wildlife is presented. In Russia, there exist several 
fragmented rabies-enzootic territories. Based on epidemiological and phylogenetic data 4 different 
areas can be distinguished: (1) central and northwestern European part of Russia with the red fox 
(Vulpes vulpes) and the raccoon dog (Nyctereutes procyonoides) as the main virus reservoirs; (2) the 
southeastern European part of Russia and southwestern Siberia where rabies is maintained 
predominantly by the red and corsac fox; (3) the southern Russian part of the Far East and (4) the 
arctic and subarctic region of Russia with the raccoon dog and the arctic fox (Alopex lagopus) as as the 
main reservoir species, respectively. Natural barriers within those areas and between areas (1) and (2) 
are not reliable, particularly during winter. Areas (3) and (4) are separated by wide zones of conifer 
forests, where the population density of the reservoir species is extremely low. These territories are huge 
and go far byond the size of vaccination areas in othe reuropean countries. Therefore oral rabies 
vaccination (ORV) can only be implemented using a step-by-step approach. Within territory (1) ORV can 
be implemented along the borders with Baltic states, Belarussia and Ukraine with the establishment of 
vaccination cordons around the metropolises of Moscow and St. Petersburg. ORV campaigns could also 
be conducted along the northern border of area (2), where the rabies incidence is low to sporadic. 
Implementation of ORV in area (3) would be suggestive as it is surrounded by broad rabies-free 
territories in the north and probably represents the northernmost spread of a common rabies enzootic 
area with China. Area (4) with circumpolar circulation of arctic rabies virus is not recommended for 
ORV because of low economic and public health significance, the vast territory and unfavourable 
climatic conditions. 
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FINNISH-RUSSIAN COLLABORATION PROGRAMME ON RABIES CONTROL IN 
WILDLIFE: THE OUTCOME OF FIVE YEARS AND THE FUTURE PROSPECTS 
A.E. Metlin
1,2,3, S.S. Rybakov
1, K.N. Gruzdev
1, V.V. Mikhalishin
1, A. Huovilainen
2 & E. Neuvonen
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1  Federal Governmental Institution “Federal Centre for Animal Health”, 600901, Yur’evets, Vladimir, Russia 
2
  Finnish Food Safety Authority, Evira, Mustialankatu 3, 00790 Helsinki, Finland 
3  Departament of Basic Veterinary Sciences, Faculty of Veterinary Medicine P.O. Box 66, Fi-00014, University of 
Helsinki, Finland 
Rabies is a serious veterinary and public health problem in Russia and in bordering countries, except Finland. In 
Finland, the last rabies outbreak occurred in 1988-1989. Thereafter re-infection of rabies from neighbouring 
regions has been prevented by oral rabies vaccination of wildlife (ORV) along the common border with Russia.  
A Finnish-Russian Collaboration Programme on Rabies Control in Wildlife was launched in 2000. The main foci of 
this programme are (i) ORV of wildlife in the Leningrad oblast and Karelia in Russia, (ii) rabies surveillance and 
monitoring of the immune status of wild animals in vaccination areas and (iii) molecular characterisation of field 
and attenuated rabies viruses. 
In the framework of the programme, so far rabies surveillance has been conducted annually and the efficacy and 
safety of two attenuated rabies vaccines, e.g. Sinrab (Russia) and Fuchsoral (Germany), has been tested in caged 
silver foxes in a comparative study. In the first vaccination campaign in Russian vaccination areas Fuchsoral 
vaccine (SAD B19) was used, whereas in subsequent years the Sinrab vaccine (RV-97) was applied annually. Since 
then, no rabies case has been detected in wildlife from vaccination areas. 
Also, more than 200 field rabies viruses (RABV) were collected in different regions of the Russian Federation and 
typed together with archived RABV from Finland and Estonia using anti-nucleocapsid monoclonal antibodies. Virus 
typing revealed five antigenic variants circulating in those regions. Subsequent genetic characterization of RABV 
revealed two distant phylogenetic groups; e.g. a Pan-Eurasian and a Caucasian group. Furthermore, the entire 
genome of the Russian vaccine strain RV-97 was sequenced and its genetic characteristics analysed. 
Finnish-Russian collaboration was considered valuable and successful by Finnish, Russian and international 
veterinary authorities and therefore, will be continued. A plan for the next 5 years has been worked out. 
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RABIES ERADICATION PROGRAMME IN ESTONIA BY MEANS OF ORAL 
VACCINATION OF WILDLIFE: FIRST RESULTS 
E. Niin, M. Laine & A. Pärtel 
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Veterinary and Food Board, Tallinn, Estonia 
The first case of sylvatic rabies in Estonia was recorded in 1968. Since then rabies is maintained in 
raccoon dogs and red foxes as well. Until 2005, the main prophylactic measure in the fight against 
rabies in animals was a compulsory vaccination of dogs and cats. In October 2005, the first large scale 
oral vaccination campaign of wildlife was carried out in the northern part of the country ranging from 
the western to the Eastern border comprising about 25,800 km2. In 2006, two vaccination campaigns 
were conducted covering the whole territory.  
Thorough rabies surveillance and monitoring of the vaccination efficiency (detection of tetracycline 
marker) was conducted to assess the success of the vaccination campaigns. As a result the number of 
rabies cases drastically decreased from 266 in 2005 to 114 in 2006. The results will be discussed in 
the context of rabies surveillance in Estonia and Europe as well. 
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RABIES SURVEILLANCE IN POLAND BETWEEN 1992 - 2006 
M. Smreczak, P. Trębas, A. Orłowska & J.F. Żmudziński 
National Veterinary Research Institute, Virology Department, 24-100 Pulawy, Poland 
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Aims/Objectives: To study the epidemiological situation of rabies in Poland between 1992 - 2006. 
Materials and Methods: Analysis of rabies data from monthly reports of the regional veterinary 
laboratories. 
Results / Discussion / Conclusions: After World War II the dog still was the main reservoir for rabies in 
Poland. Due to compulsory vaccination of dogs rabies could be successfully eliminated in domestic 
animals. Between 1949 and 1956 only single cases of rabies were diagnosed in wildlife. Unexpectedly, 
a high rabies incidence in wildlife, especially in the red fox, was reported in 1957. Since then the 
number of wildlife rabies cases steadily increased with every year. The rabies epizootics were 
characterized by seasonal and periodic fluctuations. During 1992 and 2006 a total of 22,591 rabies 
cases were detected of which 18,566 (82,2%) 3,968 (17.6%) were recorded in wildlife and domestic 
animals, respectively. 52 (0.2%) bats were found to positive for EBLVs. In domestic animals, the 
highest number of rabies cases was diagnosed in cattle – 2,414 cases – 10.7% in relation to the total 
number of rabies cases and 60.8% in relation to the number of rabies cases found in domestic 
animals. With 1,459 positive animals cats were ranked second in rabies prevalence during the past 15 
years – 6.4% in relation to the total number of rabies and 36.8% in relation to the rabies in domestic 
animals. Dogs accounted for 955 of the rabies cases representing 4.2% of the total number of rabies 
cases and 24.1% of the rabies cases found in domestic animals. The highest number of rabies cases in 
wildlife was found in red foxes. With a total of 15,583 rabies cases which equals 69% in relation to the 
total number of rabies cases and 84% in relation to the number found in wildlife, the red fox is the 
main reservoir of rabies in Poland. Rabies in raccoon dogs is an increasing problem; 1,661 cases were 
detected in raccoon dog (7.3% of total and 8.9% in relation to the number of rabies cases in wildlife). 
The peak of the rabies epizootic in wildlife was observed in 1992 resulting in 3,084 cases nationwide 
of which 2,547 cases originated from wildlife. Eighty two percent of the wildlife rabies cases were 
foxes. In 1993, for the first time oral vaccination of foxes was implemented as a new method of rabies 
control. The ORV program was started in the western part of Poland along the border with Germany. In 
subsequent years was continuously extended eastward to cover the whole territory of Poland in 2002. 
Oral vaccination campaigns are conducted twice a year (spring, autumn). After 13 years of ORV the 
rabies incidence drastically decreased by 97% from 3,084 cases in 1992 to 82 in 2006. Provided 
ORV will be continued there is hope that rabies in Poland can be eliminated in the near future. 
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EFFICACY OF A SQUARE V-RG VACCINE BAITS IN RED FOX, DOMESTIC DOG 
AND RACCOON DOG 
F. Cliquet
1, A.L. Guiot
2, C. Schumacher
3, J. Maki
3 & J. Barrat
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1  WHO Collaborating Centre for Research and Management in Zoonoses Control, OIE Reference Laboratory for 
Rabies, Community Reference Laboratory for Rabies Serology, AFSSA Malzeville, France 
2
  Conseils en Pharmacie et Biologie Santé, Lyon, France 
3  Mérial, Lyon (France) and Athens (USA) 
In response to a request of the Commission of the European Union (EU) the European Food Safety 
Agency (EFSA) has carried out a quantitative assessment of the risk of rabies introduction into the UK, 
Ireland, Sweden, and Malta as a possible result of movements of pets incubating rabies at the time of 
movement.  
The risk that a pet is incubating rabies at the time of first vaccination is equal to the prevalence of 
rabies-incubating pets in the population of origin. Despite induction of immunity by vaccination 
animals already incubating rabies will still develop clinical disease as a function of time after 
vaccination (termed type A risk). Waiting time reduces this risk.  
A small percentage of animals may not be protected after single-shot primary vaccination and hence, 
may become infected after vaccination. The risk of becoming infected after the first vaccination 
(termed type B risk) depends on the prevalence and efficiency of vaccination. Serological testing can 
be used to identify non-immune pets and will therefore reduce this risk accordingly. Type A and B risk 
were modelled as a function of waiting time after vaccination and fitted to a non-linear model 
incorporating test specificity and vaccination efficiency. 
Within the EU, the prevalence and hence the type A risk is so low, that for most countries the risk is 
negligible. However, for some countries the risk is non-negligible. In this case inclusion of a waiting 
time is necessary to reduce this risk. Here, serological testing is appropriate, because type B risk 
becomes relatively more important as type A risk is reduced with extended waiting times (over 100 
days). 
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SCENARIO-ANALYSIS EVALUATING EMERGENCY STRATEGIES AFTER 
RABIES RE-INTRODUCTION 
H.-H. Thulke
1, D. Eisinger
2, T. Selhorst
2 & T. Müller
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1
  Helmholtz Centre for Environmental Research – UFZ, Leipzig, Germany 
2  FLI-Friedrich Löffler Institut, Wusterhausen, Germany 
Aims/Objectives: After the fairly complete elimination of rabies in Western Europe using the rabies 
control strategies, e.g. ORV undertaken during the last 25 years, research is required to prepare a 
sound control strategy for emergency situations which could be a result of re-introduction of rabies from 
still infected areas. Such strategies should aim at minimizing the risk of falling back to a large-scale 
vaccination in a cost efficient manner. 
Materials and Methods: We adopted an approved spatially-explicit model on the spread and control of 
rabies to provide solutions to new problems associated with a possible re-introduction of rabies into free 
areas. We explain the logic of the model and the different options for a local emergency vaccination 
around the first detected rabies case in an area; for example ring-vaccination vs. compact area 
treatment; heavily concentrated vs. thin extended; or adaptive extension of the vaccination area. 
Results / Discussion / Conclusions: Based on systematic simulation experiments we assessed the 
performance of strategic options. Key factors such as the public health risk (i.e. number of rabies 
cases), the error risk (i.e. disease breakout from the area under control), and the budgetary risk (i.e. 
planned costs vs. potential excesses) were simultaneously considered. The results obtained often 
resulted in efficiency relations that contradict a-priori fixed intuitive management suggestions. We 
explain the causes and formulate appropriate recommendations. 
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THE FINANCIAL CHALLENGE TO KEEP A LARGE REGION FREE OF RABIES – 
THE EU EXAMPLE 
C. Freuling, T. Selhorst & T. Müller 
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Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, D-16868 Wusterhausen, Germany 
Aims/Objectives: Oral vaccination of foxes has been developed into the preferred method of rabies 
control. Since its implementation a continuous decrease in rabies incidence has been reported and 
eventually rabies was eliminated in Western Europe. Once fox rabies is eradicated in a given area, re-
infection from neighbouring infected countries is a permanent threat. In a theoretical approach we took 
the actual EU member states as a prime example, assuming these countries as being free from rabies 
but neighbouring countries still infected. The area of the vaccination belt to be established and also 
annual costs for the prevention of re-infection were calculated. 
Materials and Methods: Using GIS a 50km deep vaccination belt beyond the front of the rabies 
endemic zone, as recommended by the EU, was installed in countries bordering those regions. It was 
assumed to vaccinate twice a year, using aerial and complementary hand distribution, with a bait 
density of 25 baits per sqkm on average. Minimum and maximum prices for commercial available 
vaccine baits, aircrafts and rabies surveillance were considered for the calculation of costs.  
Results / Discussion / Conclusions: The total vaccination area to be established is about 263,000 
sqkm. With fixed-wing aircraft used, the annual cost for vaccination including rabies surveillance varies 
between a minimum of 8.2 Mio and a maximum of 16 Mio € depending on the vaccine bait cost. If 
helicopters are used exclusively, the maximum costs increase to about 24.5 Mio. Depending on the 
length of the border to infected regions, countries could pay up to 25% of the total cost. Countries 
which need to install a vaccination belt will never get a rabies free status because of the likely 
occurrence of rabies cases in border zones. 
_______________ 
  Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
46  Paris (France), 27-30 May 2007 Abstracts  RABIES PREVENTION AND CONTROL STRATEGIES  Chairman: A.D. Botvinkin 
Session 3  Rabies control in wildlife  Rapporteur: I. Kuzmin 
WHAT IS THE FUTURE OF RABIES CONTROL IN EUROPE? 
G.C. Smith
1, H.-H. Thulke
2, A.R. Fooks
3, M. Artois
4, D.W. Macdonald
5, D. Eisinger
2 & T. Selhorst
6 
1  Central Science Laboratory, Sand Hutton, York YO41 1LZ, United Kingdom 
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2  Helmholtz Centre For Environmental Research –UFZ, Leipzig, Germany 
3
  Veterinary Laboratory Agency, New Haw, Addlestone, Surrey, KT15 3NB, UK 
4  École nationale vétérinaire de Lyon, 1, av. Bourgelat, 69280 Marcy l’Etoile, France 
5  WildCRU, University of Oxford, Tubney House, Abingdon Road, Tubney, OX13 5QL, UK 
6  Friedrich Loeffler Institute, Wusterhausen, Germany 
Over the last fifteen years or so, large areas of Western Europe have been cleared of classical rabies in 
terrestrial wildlife. Over the next few years, terrestrial rabies will only occur east of a line from the 
Baltic Sea to the Adriatic Sea, with an overall aim to eliminate terrestrial rabies from the whole 
European Union. Elimination of rabies from the less rich countries of Eastern Europe and in the longer 
term the protection of Europe requires a new strategy. Here we discuss the options available to 
eliminate rabies when cost becomes an important issue, and how to maintain a ‘cordon sanitaire’ along 
the eastern boundary of the EU. This is complicated by the growing presence of the Raccoon Dog, a 
significant host for fox rabies. Minimising cost for countries is necessary where there are more 
important economic and health issues. This could be achieved either by the EU increasing the 
proportion of the cost it funds, or by changing the currently agreed vaccination strategy to reduce costs, 
but without significantly reducing the chances of rabies elimination. The cordon sanitaire may be 
placed outside the economic area of the EU, to protect the whole of the EU, or it may be placed within 
the easternmost countries to ensure logistical consistency of vaccination. However, these are the 
countries for which we must consider cost minimisation. We will suggest how models could help to 
determine these strategies, by minimising bait density, bait frequency or area. 
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THE STRENGTH OF 70% - REVISING A GIVEN THRESHOLD OF RABIES 
CONTROL 
H.-H. Thulke & D. Eisinger 
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Helmholtz Centre for Environmental Research –UFZ, Leipzig, Germany 
Aims/Objectives: Oral vaccination of foxes (ORV) requires a minimum percentage of immunized foxes to 
interrupt the infectious chain of rabies among susceptible animals and hence, successfully eliminate 
rabies. A famous estimation of this benchmark was provided by Anderson et al. as published in Nature 
in 1981. Using a population model the authors at the time raised the hope that ORV would be a 
feasible strategy for wildlife rabies control, in line with promissing field trials. By preparing standard 
applications they deduced minimum immunisation coverage of 70% required to achieve rabies 
elimination in a given area. Since then the success of ORV campaigns is measured against the 70% 
immunisation rate. Twenty five years later we were forced to re-evaluate this threshold due to 
noticeable problems with respect to increased fox densities, increasing bait densities, observed field 
data, theoretic predictions and cost-benefit analysis. 
Methods: We developed a spatially explicit rabies for the control of rabies in foxes that is keen to replay 
the dynamics of the classic population model but in the same fashion can consider the important 
peculiarities in the vaccination process, i.e. spatial distribution of infected hosts, irregular home-range 
use, heterogeneous bait coverage etc. We demonstrate that both model representations of the fox-rabies 
system equally well reproduce field data from the last 40 years.  
Results / Discussion / Conclusions: Interestingly, the more explicit model proofed that a 10 percentage-
point lower herd immunity (i.e. 60% instead of 70%) is necessary to eliminate rabies under all 
reasonable fox densities tested. The economic benefit gained from such a reduced target value of herd 
immunity was estimated in terms of baiting density. In general, 30% less resources were required to 
succesfully eliminate rabies. Thus, adapting the benchmark would save an enormous amount of 
resources in future control programs.  
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1  Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, D-16868 Wusterhausen, Germany 
2  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
3  Unité des Stratégies Antivirales, Institut Pasteur, Paris, France 
Aims / Objectives: Bat rabies in Europe is overwhelmingly caused by European bat lyssavirus (EBLV) 
types 1 and 2 (genotypes 5 and 6). Germany has reported one of the highest numbers (n = 197) of 
EBLV cases in bats in Europe during the past 50 years. All German isolates were identified as EBLV-1 
using monoclonal antibodies and a preliminary epidemiological study has indicated that there is a 
distinct geographical distribution of EBLV-1 in Germany. To further investigate the spatial and temporal 
distribution of EBLV-1 variants within Germany, and its impact on molecular epidemiology, we have 
selected 50 isolates from a total number of 12, using a random grid sampling procedure based on GIS.  
Materials and Methods: Applying a grid layer of 30 km length over the entire area of Germany to the 
geo-referenced isolates, at least one isolate of each grid cell containing EBLV isolates was randomly 
chosen. Once selected, the nucleoprotein (N) plus parts of the phosphoprotein (P) gene of each isolate 
were sequenced using direct cycle sequencing. 
Results / Discussion / Conclusions: Results of the subsequent phylogenetic analysis confirmed previous 
studies on European EBLVs showing a high sequence homology between the German EBLV-1 isolates. 
Almost identical sequence homologies within certain geographical regions indicate genomic stability 
during the transmission cycle of EBLV with little geographic spread or intermixing. Interestingly, a 6bp 
insertion, detected in the N-P intergenic region, has been repeatedly isolated from EBLV1b isolates 
from south-western Germany. 
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ASYMPTOMATIC RHABDOVIRUS INFECTION IN MERIDIONAL SEROTINE BATS 
(EPTESICUS ISABELLINUS) FROM SPAIN 
J.E. Echevarría
1, S. Vázquez-morón
1, C. Ibáñez
2, J.C. Aznar
1, E. Ruiz
3 & J. Juste
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1
  Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain 
2
  Estación Biológica de Doñana, Sevilla, Spain 
3  Laboratorio Central Veterinario, Santa Fe, Granada, Spain 
The serotine bat (Eptesicus serotinus) accounts for more than 95% of episodes resulting in human 
exposure to European Bat Lyssavirus type 1 (EBLV-1). Recent studies showed that southern Iberian 
populations of this bat species belong in fact to a sibling species named Eptesicus isabellinus. Previous 
results showed EBLV-1 RNA in the oral cavity of free-living serotine bats from southern Spain captured 
during flifgt activities, suggesting asymptomatic excretion of this virus. The aim of this work was to 
evaluate the health condition of individuals harboring EBLV-1 RNA, as well as the search for other 
rhabdoviruses. A total of 1033 animlas from 19 colonies were captured between 1998 and 2003 using 
mist-nets, subsequently ringed, weighted, sized, sexed, aged, and sampled for oro-pharyngeal swabs 
and blood, and finally released into nature. A body condition index was calculated with data for each 
individual. Serum samples were tested for EBLV-specific antibodies by fluorescent focus inhibition test 
and Lyssavirus-specific RNA in saliva swabs was detected by nested RT-PCR. Another group of 71 
saliva swabs was also analysed using another nested RT-PCR specific for the whole Dhimarhabdovirus 
complex. The results showed no temporal patterns, but might indicate an independent circulation of 
EBLV-1 among different colonies due to lack of exchange of individuals. The body condition index of 
the RT-PCR positive animals was not different from the negative ones. RNA from two apparently new 
Dhimarhabdoviruses was amplified from two bats.  
These results suggest that survival of bats after EBLV-1 infection might be possible and that other 
Rhabdovirus infections could also be a common event in this bat species. 
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PUBLIC HEALTH HAZARD OF EUROPEAN BAT LYSSAVIRUS, THE 
NETHERLANDS 
W.H.M. Van Der Poel
1,4, K. Takumi
1, E.R.A.M. Verstraten
2, P.H.C. Lina
3, J. Van Der Giessen
2 & J.A. 
Kramps
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1
  Microbiological Laboratory for Health Protection, National Institute for Public Health and the Environment 
2
  Central Institute for Animal Disease Control (CIDC– Lelystad), Lelystad, the Netherlands 
3  National Museum of Natural History “Naturalis” Leiden, the Netherlands 
4  Animal Sciences Group, Wageningen University Research 
To study the European bat lyssavirus (EBLV) epidemiology in bat reservoirs in the Netherlands, there is 
a bat lyssavirus surveillance in place since 1984. Since 1997, all detected EBLV RNAs encoding the 
nucleoprotein have been sequenced and analysed phylogenetically. To investigate how often bats come 
into contact with other terrestrial species, the nature of the contacts was determined for serotine bats 
(Eptesicus serotinus) submitted for rabies diagnosis between 2000 and 2004. PCR positive brain 
tissues do not necessarily mean that the bats can transmit the disease by biting. Therefore 30 EBLV-1a 
positive bats were additionally tested for the presence of virus RNA in other body parts. 
From 1984 to 2003, a total of 1,219 serotine bats were tested and 251 (21%) were found lyssavirus 
antigen positive. All lyssavirus sequences obtained from serotine bats originating from the years 1997 
to 2003 clustered with genotype 5 (EBLV-1) sequences. Between 2000 and 2004, thirteen people 
were bitten by bats. Five of the bats involved were identified as belonging to the subgroup EBLV-1a 
(38%). Overall prevalence of EBLV-1a in serotine bats that came into close contact with humans was 
35% (8/23). The most important finding concerning the risk of bat rabies transmission by biting was 
the presence of EBLV-1a in the salivary glands of 22 bats (73%). 
Our findings indicate that EBLVs of genotype 5 are endemic in the serotine bat in the Netherlands and 
biting incidences with humans regularly take place. Therefore, a public health risk of bat acquired 
rabies cannot be ignored. As EBLVs can cause fatal infections in humans, bats involved in contact 
incidents with humans should be tested to determine if the victim was exposed to EBLVs. For this 
purpose, in the Netherlands a nation-wide passive surveillance program is put in place and an active 
surveillance program will be started in 2007. 
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SEROLOGICAL INVESTIGATION OF BATS INFECTED WITH RABIES VIRUS IN 
CHINA 
L. Wang
1, Y. Jiang
1, Z. Lu
3, K. Sun
4, H. Xuan
2, A.R. Fooks
5 & C. Tu
1 
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  Academy of Military Medical Sciences, Changchun, 130062, China 
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2
  Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China 
3
  Foshan University, Foshang, 528000, China 
4  Northeast Normal University，Changchun, 130062, China 
5  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
In order to investigate rabies virus infection of bats in China the indirect fluorescent antibody test (IFA) 
using a FITC-conjugated Protein A/G mixture was established for detection of rabies specific antibodies. 
A total of 685 serum samples from frugivorous and insectivorous bats belonging to 8 different species 
of 4 bat families originating from 10 different areas of 4 provinces in China were tested using the IFA 
and a modified fluorescent antibody virus neutralization test (mFAVN). The results showed that 2.2% 
(15/685) of the bats tested were RABV antibody positive representing 3 different species, e.g. Rosettus 
leschenaulti,  Rhioophus blythi and Rhinolophus ferrumequinum. Bats of the species Rosettus 
leschenaulti were found positive in 3 of 4 provinces suggesting a wide geographic range of infection for 
this species. Moreover, the IFA results were confirmed by mFAVN, which was used to test samples with 
sufficient amount of serum; 3 IFA positive sera were also positive in mFAVN although exhibiting very 
low titers (0.15, 0.08, and 0.33 IU/mL), while 15 IFA negative serum samples were also negative in 
mFAVN, indicating a 100% concordance of the two methods. The low antibody titers in all positive 
serums imply that natural infection of RABV in bats most likely induce low levels of antibody 
responses. This is the first report about natural infection of RABV in bats in China. The role of bats in 
rabies transmission amongst human and dogs requires further investigation with respect to severe 
epidemics of human rabies in China. 
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EPIDEMIOLOGY AND PATHOGENICITY OF AFRICAN BAT LYSSAVIRUSES 
W. Markotter, C. Wilsenach, L.H. Nel et al. 
Department of Microbiology, Faculty of Natural and Agricultural Sciences, University of Pretoria, 0001 South 
Africa 
 
S
S
S
3
3
3
 
 
 
•
•
•
 
 
 
R
R
R
a
a
a
b
b
b
i
i
i
e
e
e
s
s
s
 
 
 
i
i
i
n
n
n
 
 
 
b
b
b
a
a
a
t
t
t
s
s
s
 
 
 
 
Viruses belonging to all four known African lyssavirus genotypes (gt’s) have been reported and isolated 
almost exclusively from South Africa over the past few decades. These are: (1) Duvenhage virus (gt 4), 
isolated in 2006 from a human fatality for the first time in 36 years; (2) Mokola virus (gt 3), isolated 
irregularly, mostly from cats; (3) Lagos bat virus (gt 2) continually isolated from Epomophorus fruit bats 
and from incidental terrestrial animals during the past 3 years; (4) Rabies virus (gt 1) – with two virus 
biotypes being endemic in mongooses and in canines (domestic and wildlife), respectively. 
Only two of these are associated with bats in southern Africa, viz. Duvenhage virus and Lagos bat virus 
(gt’s 4 and 2). We are interested in the evolutionary history and likely future of these unique viruses. 
Therefore, for both these genotypes we have embarked on a programme of comparative study of the 
molecular epidemiology and pathogenicity of all the virus isolates in existence. For Duvenhage virus, 
full-length genome sequences indicated a pattern of evolution strikingly similar to that observed for 
European bat lyssavirus 1. In the case of Lagos bat virus, individual isolates were found to differ 
dramatically with respect to molecular genetic and pathogenicity profiles. 
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EXPERIMENTAL INFECTION OF BIG BROWN BATS (EPTESICUS FUSCUS) 
WITH WEST CAUCASIAN BAT VIRUS 
I.V. Kuzmin, R. Franka & C.E. Rupprecht 
Centers for Disease Control and Prevention, Atlanta, GA, USA 
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The aim of the study was to assess the susceptibility and general pathogenesis patterns of West 
Caucasian Bat virus (WCBV) in big brown bats. The bats, either recently captured and survivors from 
the previous experiments with other lyssaviruses were inoculated intramuscularly into masseter (7), 
neck (8) or orally (6). They were bled prior to inoculation and bi-weekly thereafter. Oral swabs were 
taken weekly during the first 3 months and bi-weekly during the next 3 months. Several tissues of bats 
that died during 6 months of observation, as well as brains and salivary glands of survivors, all oral 
swabs and blood pellets were subjected to nested RT-PCR. The PCR-positive samples were additionally 
subjected to virus isolation. Serum samples were studied for the presence of virus-neutralizing 
antibodies. 
As a result, 3 bats developed rabies and died on days 10, 10 and 18. All 3 were inoculated into neck. 
Viral RNA was detected in a number of tissues but isolation was successful only from the brain. An oral 
swab of one of these bats was also PCR-positive, however the isolation attempt failed. Brains, salivary 
glands and swabs from survivors were negative, as well as all blood pellets collected. WCBV-neutralizing 
antibodies were identified in 4 bats, all inoculated into masseter. They appeared 14-80 days post 
challenge, were highest up to 5th months, and decreased by the end of observation. The bats that 
previously survived challenge with Irkut virus still maintained remnant Irkut-neutralizing antibodies; 
however, challenge with WCBV did not boost their titers. 
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SUSCEPTIBILITY OF FOXES (VULPES VULPES) TO EUROPEAN BAT 
LYSSAVIRUSES TYPES-1 AND -2 
F. Cliquet
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2  WHO Collaborating Centre for the Characterization of Rabies and Related Rabies Viruses, OIE Reference 
Laboratory for Rabies, Rabies and Wildlife Zoonoses Group, Veterinary Laboratories Agency, Weybridge, United 
Kingdom 
The objective of the AFSSA/VLA collaborative study was to assess the susceptibility of silver-haired 
Norwegian foxes to European Bat Lyssavirus types 1 and 2 (EBLV-1 and EBLV-2). Both EBLV-1 and 
EBLV-2 have been isolated in European bats since 1954, mainly in Eptesicus serotinus and Myotis 
species. Since 2000, the number of reported cases has increased due to enhanced in epidemiological 
surveillance of bat rabies throughout Europe. Although more than eight hundred EBLV cases have been 
reported in bats in Europe, EBLV-1 and -2 viruses have been rarely reported to infect humans and 
terrestrial animals.  
Silver foxes were susceptible to EBLV infection (3-4 log dosis) following direct intracranial inoculations, 
100% mortality during 8-282 days post-infection. However, the susceptibility of the foxes was low 
following peripheral (intramuscular) inoculation with a similar dose; EBLV-1 infection resulted in 19% 
(n=4/21) mortality with an incubation period of 14-24 days. None of the animals challenged with 
EBLV-2 succumbed to disease. Further analysis is in progress to investigate whether the infected foxes 
excreted infectious virus in saliva. 
These data suggest that bat to fox spillover of EBLVs is possible, with a greater probability of spillover 
for EBLV-1 than EBLV-2. 
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IDENTIFICATION OF BRITISH BAT SPECIES USING SEQUENCE COMPARISON 
AND ITS APPLICATION TO EUROPEAN BAT LYSSAVIRUS DIAGNOSIS AND 
SURVEILLANCE 
S.L. Harris
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2, A.R. Fooks
2, G. Jones
1 
 
S
S
S
3
3
3
 
 
 
•
•
•
 
 
 
R
R
R
a
a
a
b
b
b
i
i
i
e
e
e
s
s
s
 
 
 
i
i
i
n
n
n
 
 
 
b
b
b
a
a
a
t
t
t
s
s
s
 
 
 
 
1
  School of Biological Sciences, University of Bristol, Woodland Road, Bristol, BS8 1UG, United Kingdom 
2  Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
The United Kingdom has performed passive surveillance for European bat lyssaviruses (EBLVs) since 
1985, and active surveillance since 2003. A critical component of these studies is the accurate 
identification of bats either submitted for testing or sampled in the field. Identification is currently 
dependent on a number of morphological characteristics. Whilst this is an effective means of bat 
identification a number of problems remain with this approach. It relies on the experience of bat 
handlers and can lead to problems in differentiating members of the Myotis genus, particularly between 
Myotis mystacinus (Whiskered bat) and Myotis brandtii (Brandt’s bat). Furthermore degradation of bats 
submitted for testing can also lead to problems in making an accurate species identification. 
Comparison of genetic sequence data could offer an alternative approach to differentiating bat species 
when morphological characterisation is not possible. Using tissue samples from UK resident bat 
species, sequence analysis of the mitochondrial DNA Cytochrome b gene, and the β-actin gene allowed 
identification of many of the most commonly found bat species in the UK, and genetic separation of 
two morphologically cryptic species. Application of this approach identified the species of a bat 
infected with EBLV-2 found in Surrey as Myotis daubentonii (Daubenton’s bat). Furthermore, 
haplotyping of the Cytochrome b gene enabled further characterisation of native bat species. This could 
provide a useful tool to assist in conservation strategies. 
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HUMAN RABIES INCLUDES EARLY GENERALIZED VASOSPASM OF CRANIAL 
ARTERIES THAT RESPONDS TO TETRAHYDROBIOPTERIN, L-ARGININE OR 
NITROPRUSSIDE 
R.E. Willoughby
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1  Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America 
2  Children’s Hospital of Oakland, Oakland, California, United States of America 
3  Riley Hospital for Children, Indianapolis, Indiana, United States of America 
4  Viral and Rickettsial Disease Laboratory, Richmond, California, United States of America 
5  Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America 
6
  Horizon Molecular Medicine, Atlanta, Georgia, United States of America 
Aims / Objectives: In 2004, a teenager survived bat-associated rabies through the Milwaukee protocol. 
This survivor and a patient with dog-associated rabies developed deficiencies in tetrahydrobiopterin 
(BH4) and associated neurotransmitters. BH4 is essential for neuronal nitric oxide synthase (nNOS), so 
rabies is predicted to cause constriction of cerebral arteries. We sought medically significant spasm of 
the middle cerebral arteries (MCA) by transcranial doppler (TCD). 
Materials and Methods: Case-report methodology. Flow velocities and resistive indices (RI) of MCA were 
obtained daily by TCD. 
Results / Discussion / Conclusions: One child with bat-associated rabies developed severe spasm of 
MCA on day-8 of hospitalization that responded to 0.2 mcg/kg/min nitroprusside. Onset of systemic 
immunity resulted in clearance of virus from saliva by PCR. The child died of cerebral edema on day-
25, associated with thrombosis of cerebral venous sinuses. One child with dog-associated rabies 
developed spasm of MCA on day-7 of hospitalization that responded to 6 mg/kg/day BH4. A second 
spasm with high RI (without cerebral edema) responded to 20 mg/kg/day BH4 and 0.5 g/kg/dose L-
arginine. Onset of systemic immunity resulted in partial clearance of virus from saliva by PCR. In 
retrospect, the second spasm caused brainstem ischemia. The child died of cerebral edema on day-27, 
without sinus thrombosis. Cerebral artery vasospasm occurred on day-7-8 of hospitalization for 2 
children with rabies, but was clinically silent by standard monitoring. Spasm responded to drugs 
directed at the NOS pathway. Animal models for treatment of rabies are sorely needed to evaluate 
therapeutic options. 
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THERAPY OF HUMAN RABIES: LESSONS FROM EXPERIMENTAL STUDIES IN 
A MOUSE MODEL 
A.C. Jackson, C.A. Scott, J. Owen, S.C. Weli & J.P. Rossiter 
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Departments of Medicine (Neurology), Microbiology and Immunology, and Pathology and Molecular Medicine and 
Centre for Neuroscience Studies, Queen’s University, Kingston, Ontario, Canada K7L 3N6 
Human rabies is almost always fatal. Ketamine was one of the therapeutic agents used on a survivor 
who did not receive vaccine. The therapy was based on previous experimental work performed in 
primary neuron cultures and in a rat model of rabies. We have reexamined ketamine therapy in infected 
mouse primary neuron cultures and in adult ICR mice using the CVS strain with both intracerebral and 
peripheral routes of inoculation with ketamine (120 mg/kg/day) vs. vehicle given intraperitoneally. We 
did not observe any significant beneficial therapeutic effect of ketamine in the cultures or mouse 
models. We do not recommend further widespread clinical use of ketamine on human rabies patients 
until further experimental work confirms therapeutic efficacy. 
Because of the potential neuroprotective and anti-apoptotic properties of minocycline, we also assessed 
minocycline therapy in infected primary neuron cultures and in neonatal ICR mice infected by 
peripheral inoculation with a highly attenuated rabies virus strain (D29). No beneficial effect of 
minocycline was observed in the primary neuron cultures. In the mouse model, minocycline therapy (50 
mg/kg/day for 18 days) aggravated the clinical neurological disease and resulted in higher mortality. An 
anti-apoptotic effect of minocycline was noted in brains of infected mice, which may have very mildly 
increased viral spread. An anti-inflammatory effect of minocycline was also noted in the brain using a 
CD3 T cell marker. These effects likely aggravated the disease. Consequently, we recommend that 
empirical therapy with minocycline be avoided in the management of rabies and viral encephalitis in 
humans until the results of more experimental work becomes available. 
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National Center for Disease Control, 9, M.Asatiani str., 0177, Tbilisi, Georgia 
Objectives: In 2006, there was a relatively high incidence of rabies post-exposure prophylaxis (PEP) of 
about 876 / 100,000 persons annually in Georgia. The aim of this study was to improve post-exposure 
policy and practice, as well as to to determine priorities for a rabies surveillance and control at a 
national level. 
Method: Analysis of data from the National Center for Disease Control on rabies surveillance in the 
years 2004, 2005 and 2006. 
Results: Between 1986-1995 a total of 40 rabies cases in humans were reported in Georgia. In 2004, 
2005 and 2006 a total of 12, 10 and 17 rabies cases were officially reported, respectively, 
representing a significant increase in overall incidence compared to a decade ago. About 93% of the 
rbaies cases were caused by dog bites. A high population of stray and /or ownerless dogs and a high 
percentage of unvaccinated pets were identified as major risk factors.  
In 2006, there were 38,569 patients having received PEP following exposure to suspect rabid animals 
compared to 23,712 and 30,254 in 2004 and 2005, respectively, representing an increase of about 
one third. From the total of PEPs initiated in 2004, 2005 and 2006, 70 % (16,568), 76% (23,106) 
and 78.4% (30,254) were discontinued, respectively, because the biting animals remained healthy 
during the required observation period. Safety concerns concerning available immunoglobulins, 
uncertainty in usage of commercially available vaccines and immunoglobulins and inconsistency of 
treatment guidelines with international recommendations are considered obstacles for better 
adminstration of PEP. 
Conclusions: For an effective prevention of rabies in humans strikt implementation of international 
guidelines on the use of rabies vaccines and immunoglobulins in PEP at a national level is needed. 
National rabies eradications programs as well as attempts to control stray dogs must be implemented to 
reduce the risk of transmisson of rabies to humans. 
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A SIMPLIFIED ECONOMICAL 4-SITE INTRADERMAL POST-EXPOSURE RABIES 
VACCINE REGIMEN IS AS IMMUNOGENIC AS THE CURRENT 
INTRAMUSCULAR AND INTRADERMAL METHODS 
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M.J. Warrell
1, A. Riddell
1, L.-M. Yu
1, J. Phipps
1, L. Diggle
1, J. Deeks
1, H. Bourhy
2, L. Audry
2, A.R. 
Fooks
3, S. Brookes
3, F.-X. Meslin
4, R. Moxon
1, A.J. Pollard
1 & D.A. Warrell
1 
1  Oxford Vaccine Group, Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford UK 
2  UPRE Lyssavirus Dynamics and Host Adaptation, Institut Pasteur, Paris, France 
3  Rabies Unit, Veterinary Laboratories Agency, New Haw, Surrey; UK 
4  WHO, Geneva, Switzerland 
Economical intradermal (ID) rabies post-exposure prophylaxis (PEP) regimens use only 40% of the 
amount of vaccine required for the familiar intramuscular (IM) regimen, yet they are used for only 3% 
of 5 million annual tissue culture vaccine treatments in Asia, and are not used in Africa. This is 
because of confusion over regimens, lack of confidence in ID injection technique, and fear of reducing 
the vaccine dosage. Their use has been restricted to large immunisation clinics. 
The immunogenicity of a simplified 4-site intradermal regimen was compared with the two current ID 
PEP regimens, and the standard IM regimen in a randomised single blind controlled trial, using 
purified vero cell rabies vaccine. The regimen is adapted from the current 8-site method: four ID sites 
on day 0, two sites on day 7 and single sites on days 28 and 90. Rabies antibody was measured on 
days 0, 7, 14, 90 and 1 year after immunisation. 
All the ID regimens proved equally immunogenic and were not inferior to the IM treatment. The 4-site 
regimen has advantages over current regimens including one less visit than the 2-site ID method and it 
can be used economically with all WHO recommended vaccines. Injecting a whole ampoule of vaccine 
divided between ID sites on day 0 is more practicable for widespread use and is safer, especially in 
inexperienced hands. 
An increased uptake of ID PEP methods and reduction of cost could be achieved by introducing this 
regimen, which proved at least as immunogenic as the more expensive IM regimen. 
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2  Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand 
3  Provincial Public Health Office of Pitsanulok, Thailand 
Background: Pre-exposure rabies vaccination is recommended for travelers to endemic countries. It 
consists of three injections administered over 2-4 weeks. Travelers often do not have enough time to 
receive a complete course prior to departure and leave with only one or two injections. 
Objective: To evaluate the secondary antibody response in volunteers who received one or two injections 
of PVRV or PCEC compared to the recommended 3 injections regimen when administered booster one 
year later. 
Result: All volunteers developed an accelerated antibody response within 7 days when given boosters. 
Conclusion: One injection pre-exposure rabies vaccination is enough to prime the host immune memory 
for at least one year. 
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Division of Research Affairs and Infectious Diseases, Faculty of Medicine, Chulalongkorn University, 10330 
Bangkok, Thailand 
Objective: To determine whether volunteers who had received a rabies vaccination 5-10 years or 10-21 
years previously would still respond with an accelerated immune response to booster injections with 
tissue and avian culture rabies vaccines. 
Method: Records of patients from the Queen Saovabha Memorial Institute who had pre-or post-exposure 
rabies prophylaxis with a tissue culture vaccine were identified randomly and were asked to provide 
blood samples. They then received two 0.1 mL intradermal booster injections of purified Vero cell 
rabies vaccine on days 0 and 3 and were followed by determination of neutralizing antibody on days 5, 
7 and 14. A total of 118 volunteers were recruited. Sixty-five had been vaccinated 5-10 years 
previously and 53 had been vaccinated 10-21 years earlier. 
Results: One healthy female 75 years of age had a detectable antibody level on day 0 (0.08 IU/mL) 
which increased to 0.11 on day 5 and to 0.48 IU on day 7. It rose to 6.25 on day 14. All remaining 
subjects had detectable antibody titers on day 0 and titres above 0.5 IU/mL on day 7. This indicated 
an accelerated immune response. Statistical analysis showed no significant differences between 
subjects who had received pre-or post-exposure vaccination, intradermal or intramuscular injections, 
additional immunoglobulin, or sex and age. 
Conclusion: Tissue and avian culture rabies vaccination confers long lasting immune memory in normal 
hosts. 
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Y. Rotivel
1, M. Goudal
1, A. Simons De Fanti
2, D. Van Der Vliet
2 & French Rabies Treatment Centres
3 
1  Rabies Treatment Centre, Medical Centre, Institut Pasteur, Paris, France 
   National Reference Centre for Rabies, Institut Pasteur, Paris, France 
2
  Rabies Treatment Centre, Medical Centre, Institut Pasteur, Paris, France 
3  List of French Rabies Treatment Centres on: www.pasteur.fr/sante/. 
In 1968, an epizooty of fox rabies reached the French territory. In the following years, the National 
Reference Centre for Rabies was founded at the Pasteur Institute, Paris. Among others, its main tasks 
included the surveillance of rabies cases in humans as well as the consultation and application of 
rabies post-exposure prophylaxis (PEP). Surveillance has been effective since 1982. A Bulletin on the 
Epidemiology and the Prophylaxis of Rabies in Humans in France is being published every year. This 
Bulletin is now available on the Internet for both national and local human health authorities as well as 
veterinary authorities. Since 2005, data are collected with the new software Voozanoo
® directly via the 
Internet. 
Since 1970, twenty cases of rabies in humans have been reported in France; however, none of the 
rabies cases was acquired in the country. The number of PEP was highest in 1990, when the number 
of rabies cases in wildlife peaked out. Due to the decline of rabies cases in the wildlife in subsequent 
years, the number of PEP decreased by 60%. Nevertheless, about 4,000 people had to receive PET. 
Those patients either were persons with a work-related predisposition or persons who had been exposed 
to bats or rabid animals illegally introduced to French territory or during a stay in countries where 
rabies ist still enzootic. 
Based on the information of this database the follwoing conclusions can be drawn: 
- Human rabies cases are mainly due to (i) canine rabies virus variants acquired directly in 
countries with enzootic canine rabies, (ii) exposure to rabid animals illegally translocated to 
France, or (iii) through iatrogenic exposure 
-  In recent years bats appear to become an increasing source of exposure; 
- PEP surveillance is of utmost importance to monitor and to improve the quality of case 
management.  
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Rabies virus (RABV) is a pathogen well-adapted to the nervous system, where it infects the neurons. 
RABV is transmitted by the bite of an infected animal. It enters the nervous system via a motor neuron 
through the neuromuscular junction, or via a sensory nerve through nerve spindles. It then travels from 
one neuron to the next, along the spinal cord to the brain and the salivary glands. The virions are then 
excreted in the saliva of the animal and can be transmitted to another host by bite. It is intriguing to 
note that RABV progression is interrupted neither by destruction of the infected neuron nor by the 
immune response. Thus, it is likely that RABV has developed a subversive strategy to avoid functional 
neuron impairment which compromises the infectious cycle. We showed that rabies virus 
neuroinvasiveness results of two factors : 1) not only neurotropic rabies virus avoids to induce neuron 
cell death, but also 2) “protective “T cells that migrate into the infected nervous system are killed by 
apoptosis, as a result of the overexpression of immunosubversive molecules such as Fasl, HLA-G or B7-
H1 in the infected nervous system. Our data suggest that the preservation of the neuronal network and 
the destruction of T cells that invade the nervous system in response to the infection are crucial events 
for rabies virus neuroinvasion and for transmission of rabies virus to another animal. This may shed new 
lights for improvement of post-exposure treatments of rabies. 
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1
  Faculty of Medicine and Pasteur Institute, Novi Sad, Serbia 
2  Department of Veterinary Medicine, Faculty of Agriculture, Novi Sad, Serbia 
Aims: Rabies vaccines produced on BHK-21 (C-13) cell culture are well-known for veterinary use. 
Research initiated by WHO raised great expectations on the usefulness of such vaccines for humans. 
Based on experimental results the designed product is safe due to virus inactivation by beta-
propiolactone destroying DNA contamination from cell culture. 
Materials and Methods: We propagated the Pasteur viurs (PV) strain of rabies virus in BHK-21 (C-13) 
cells and produced a beta-propiolactone inactivated and aluminium-phosphate adsorbed rabies 
vaccine. In a clinical trial, a total of 300 adult subjects were vaccinated. Three doses of vaccine were 
administered intramuscularly in the deltoid region follwoing the 0-7-21pre-exposure vaccination 
regimen. At day 30 post vaccination blod smaples were drawn and virus neutralising antibodies (VNA) 
were measured by RFFIT. 
Results: Local reactions in few percents and no sistemic adverse reactions were registered. All 
volunteers had titer over 0.5 IU/ml. 
Discussion: Rabies vaccine produced on BHK-21 (C-13) cells has been used for animals for a long 
time. Those rabies vaccines have been shown to be safe. Contamination with cellular DNA is not 
dangerous because the treatment with beta - propiolactone during virus inactivation completely 
inactivates the biological activity of DNA. This finding, which was accepted also by WHO, encourages 
the use of BHK cells as substrate for human vaccine production. 
Conclusions: We conclude that this low cost vaccine is safe and effective for humans. The preliminary 
results with BHK/21 vaccine from clinical trials confirmed its good tolerance and immunogenicity. 
_______________ 
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1
  Institute of Virology, Justus-Liebig-Universität Giessen, D-35392 Giessen, Germany 
2  Paul-Ehrlich-Institut, D-63207 Langen, Germany 
Pre-expositional vaccination against rabies virus is a highly effective method to prevent rabies in 
humans and animals. For travel purposes vaccination of domestic carnivores is obligatory. In addition 
some countries demand testing on virus neutralizing antibodies (VNA) against rabies. The minimal 
threshold level accepted by WHO/OIE is 0.5 IU/ml. Despite orderly vaccination some animals do not 
reach the threshold.  
Aims / Objectives: Identification of specific risk factors in dogs and cats with respect to VNA titres < 
0.5 IU/ml after vaccination as measured by the FAVN-Test. Review of rabies vaccination protocols and 
recommendations with regard to travel regulations. 
Materials and Methods: To collect comprehensive data on vaccination history from animals tested for 
rabies VNA a standardised questionnaire was developed and sent to veterinarians who submitted sera 
for testing. Data on species, age, sex, breed, vaccine used, date of last vaccination and blood sampling, 
vaccination history and further medical treatment at the time of vaccination were collected. Data sets 
of about 1200 animals were analysed. 
Results / Discussion / Conclusions: Most animals older than one year already received more than one 
rabies vaccination. The influence of breed and sex on the VNA titre seems to be insignificant. Young 
dogs after their first vaccination have a high risk of developing VNA titres < 0.5 IU/ml. The risk can be 
minimised by application of a second vaccination and blood sampling according to the 
recommendations of the manufacturer. An important factor for the test outcome in seroneutralsiation 
assays (FAVN) might be the virus strain used in the vaccine. 
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1
  United States Department of Agriculture, Animal and Plant Heath Inspection Service, Wildlife Services, Concord, 
NH 03301 USA 
2  Poxvirus and Rabies Section, Centers for Disease Control and Prevention, Atlanta, GA 30333 USA 
3  Rabies Unit, Ontario Ministry of Natural Resources, Peterborough, Ontario K9J8N8 Canada 
4  New Brunswick Department of Health and Wellness, Fredericton, New Brunswick, E3B 5G8 Canada 
5  Agency of Health and Social Services of Montérégie, Longueuil, Québec, J4K 2M3 Canada 
6  United States Department of Agriculture, Animal and Plant Heath Inspection Service, Wildlife Services, 
Castleton, NY 12033 USA 
7  United States Department of Agriculture, Animal and Plant Heath Inspection Service, Wildlife Services, 
Washington, DC 20250 USA 
Prior to 1977, raccoon rabies was confined to the southeastern United States. Raccoon translocations 
from Florida to western Virginia-West Virginia can be attributed to emergence of this rabies virus variant 
in the mid-Atlantic region, which has spread to the north, with incursions into Ontario, Quebec, and 
New Brunswick, Canada, and as far west as northeast Ohio. Raccoon rabies also spread southward, with 
its current distribution contiguous from southwest Alabama to southeastern Canada. Since 1998, a 
growing coalition of state, federal, county and municipal as well as Canadian and Mexican expertise has 
collaborated on rabies management goals and strategies to prevent raccoon rabies from gaining an 
increasing foot-hold in North America. Coordinated programs have been established from Maine to 
Alabama to contain raccoon rabies, while exploring elimination strategies. Successes in containing 
raccoon rabies have been realized through strategies that rely predominantly on oral vaccination. 
International coordination of programs targeting raccoon rabies continues in eastern Canada, where 
contingency actions have led to elimination or near elimination in Ontario and New Brunswick. 
However, increasingly, focus in the United States has been directed toward contingency actions to 
“hold-the-line” on raccoon rabies spread beyond existing ORV zones (e.g. Vermont, Ohio) or untreated 
areas (Alabama, Tennessee) where it threatens to spread, rather than increasing emphasis on broader 
raccoon rabies elimination. We report on these management challenges; progress on initiatives toward 
new or improved baits, biologicals, and strategies; and a shift toward increasing continental 
collaboration on rabies control to better assure long-term success in raccoon rabies management. 
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Objective: To analyse the stability of oral rabies virus vaccine baits in terms of virus titre and physical 
stability of the bait casing over a two week observation period in relation to air temperature, sunlight 
and rainfall. 
Materials and Methods: Two batches of Lysvulpen vaccine produced by Bioveta (Czech Republic) were 
tested. The vaccine titre indicated by the producer was not less than 107,0 TCID50/dose. A 100 
vaccine baits each were distributed by hand in the forest and in the outskirts of the forest in spring and 
autumn. Air temperature, precipitation and sunlight were daily recorded and the shape and consistency 
of the vaccine bait casing was documented. Vaccine titration ws conducted at the Lithuanian National 
Veterinary Laboratory, Kaunas.  
Results: The mean air temperature during the spring test period was 10,0 ºC (10,0 ºC ±1,1 ºC) and 
18,9 ºC (18,9 ºC ±3,5 ºC) during night and day, respectively. It was sunny, no rainfall. The baits, 
distributed in the forest, were totally covered by the casing for 12 days of the two observation period. 
On day 3 and 6 the bait casing of 23% and 19% of the tested baits became soft and sticky. On day 6 
and 9 one and two baits were disintegrated, respectively, and the vaccine capsule was visible. The 
vaccine titre on day 9 was 105.6 TCID50/dose. The casing of baits distributed in the outskirts of the 
forest became soft and sticky on day 3. On day 9 all tested vaccine baits were deformed and 17 out of 
27 baits were disintegrated with the vaccine capsules visible. The vaccine titre on day 9 was 103.75 
TCID50/dose. The mean air temperature during the autumn test period was 1,5 ºC (1,5 ºC ± 0,8 ºC) 
and 2,5 ºC (2,5 ºC ± 1,0 ºC) during night and day, respectively. It was heavy rainfall. On day 1 the 
casing of the baits became soft and sticky and on day 3 the vaccine capsule was visible. The vaccine 
titre on day 3 decreased to 104.4 TCID50/dose. 
Discussion and conclusions: Stability of rabies vaccine baits in the field is very important for the 
success of oral vaccination against rabies. Some experiments showed that field efficacy of oral rabies 
virus vaccines depend on the dose and stability of the vaccine virus titre and of the bait casing. In our 
experiment we demonstrated that the bait casing was more stable in shadow than in sunlight and bait 
casing became soft and melted in rainfall. The vaccine virus titre was enough stable in dry conditions 
and vaccine virus titre decreased rapidly in wet conditions. Distribution of baits in rainfall can 
compromise the efficacy of the oral vaccination program if the baits are not rapidly consumed by 
wildlife. 
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2  All-Russian Research Institute of Veterinary Virology and Microbiology, Pokrov, Russia 
Objectives: The immunogenic properties of the attenuated rabies virus strain ERA G 333, a proposed 
candidate for oral rabies vaccine in Russia, in foxes and raccoon dogs after oral administration were 
examined. As demonstrated previously, ERA G 333 (provided by the Centers for Disease Control and 
Prevention in the framework of the Biotechnology Engagement Program) is apathogenic for 3-week old 
and adult mice, for other target and non-target species, even when administered intracerebrally. 
Materials and Methods: Ten foxes aged 7 to 8 month and 8 wild captured raccoon dogs were orally 
vaccinated with 2.0 ml of ERA G 333 (titer 107.5 FFU) by direct admisnistration on the tongue. 
Another 3 foxes and 3 raccoon dogs were used as controls. Blood samples were collected prior to 
immunization and 60 days post vaccination. Virus neutralising antibody (VNA) titers were determined 
by the fluorescent antibody virus neutralization (FAVN) test. 
Results: Eight foxes and four raccoon dogs showed seroconversion on 60 day post vaccination. In six 
foxes and three raccoon dogs rabies VNA- titers exceeded 0.5 IU/ml.  
This study demonstrated the principle possibility of the use of ERA G 333 for oral vaccination of red 
foxes and raccoon dogs. However, further experiments are needed to determine the effective doze, virus 
stability, strength and duration of the immunity. 
_______________ 
Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
Paris (France), 27-30 May 2007  69 Abstracts  ADVANCES IN TECHNOLOGIES, DIAGNOSIS AND VACCINES  Chairman: N. Tordo 
Session 4    Rapporteur: T. Hemachuda 
CANINE ADENOVIRUS-BASED VACCINES AGAINST RABIES 
N. Tordo
1, A. Fournier
2, C. Jallet
1, M. Szelechowski
2, B. Klonjkowski
2 & M. Eloit
2 
1  Unité des Stratégies Antivirales, Institut Pasteur, Paris, France 
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2  UMR 1161 Virologie, INRA-AFSSA-ENVA – Maisons-Alfort, France 
Adenovirus based vectors are very attractive candidates for vaccination purposes as they induce in 
mammalian hosts potent humoral, mucosal and cellular immune responses to antigens encoded by the 
inserted foreign genes. We have generated E1-deleted and replication-competent recombinant canine 
adenoviruses type-2 expressing the rabies virus glycoprotein (G). The effectiveness of both vectors to 
express a native G protein have been characterized in vitro in permissive cell lines. Following 
intramuscular (im) or oral inoculation in mice, we have compared the humoral and cellular immune 
responses offered by the canine vectors with an Ad5 E1-deleted virus. Humoral responses specific of 
both adenovirus and the rabies glycoprotein antigens were studied. An influence of the mouse strain 
was observed using replication-competent canine adenovirus. High levels of rabies-neutralizing 
antibody were observed upon im inoculation, lower but significant levels upon oral immunization. 
100% and 80 % of mice inoculated by the muscular and the oral route, respectively, resisted to a 
lethal peripheral challenge. These results are very promising in the perspective of oral vaccine for dog 
rabies control. 
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1
  National Center of Veterinary Microbiology (CENID-Microbiología), INIFAP, Mexico 
2  Faculty of Chemistry-UNAM 
3 CINVESTAV-IPN 
The availability of plant-based rabies vaccines for veterinary use would facilitate distribution, 
administration and long-term storage. The aim of this work was to obtain transgenic maize expressing 
the rabies virus G protein of Vnukovo strain and to evaluate immunogenicity in mice, by oral route. We 
employed the ubiquitin maize promoter fused to the whole coding region of rabies virus G gene, and a 
constitutive promoter from cauliflower mosaic virus (CaMV). Maize embryogenic calli were transformed 
with the above construct by biolistics. Regenerated maize plants were recovered and grown in a 
greenhouse. The presence of G gene and its product was detected by PCR and Western blot, 
respectively. Co-integration percentage in analyzed plants was of 93.3%. The amount of G protein 
detected in the grains was approximately 1% of the total soluble plant protein. Transformed kernels 
containing 50 µg of G protein were given once by oral route in adult mice (BALB-C strain). Challenge 
was done at 90 days post-vaccination using a lethal dose of a vampire bat rabies virus (100 LD50% in 
mice). The edible vaccine was able to induce neutralizing antibodies which were able to protect mice in 
100%, against challenge with a vampire bat-strain, which is one of the main reservoirs in Latin 
America. Control group did not survive. G protein of Vnukovo strain expressed in transgenic maize may 
work as oral immunogen against rabies, provoking cross protection. 
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2 & K. Dellagi
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Laboratoire Immuno-Biotechnologie 
1  Unité Spécialisée Rage 
2
  Institut Pasteur de Tunis, 13, Place Pasteur BP74 1002, Tunis-Blevedere, Tunisia 
Aims / Objectives: The most widely used test for rabies diagnostics is the Fluorescent Antibody Test, 
which is recommended by both WHO and OIE. This test may be used directly on a smear, and can also 
be used to confirm the presence of rabies antigen in cell culture or in brain tissue of animal that have 
been inoculated for diagnosis. The colorimetric enzymes are usually coupled to an antibody by 
chemical means using cross-linking reagents. However, such non-specific procedures lead to 
heterogeneous conjugates, sometimes with reduced activity and specificity. To by–pass these problems, 
genetic engineering has provided a way to create chimeric bifunctional molecules in which the variable 
domains of an antibody are genetically linked to unrelated proteic tracers. In this study, our objective is 
to design a novel class of “artificial antibodies” based on a alkaline phosphatase protein-labeled 
recombinant antibody to develop a simple colorimetric immunoassay method for detecting in vitro the 
rabies virus glycoprotein in an environmental sample. 
Methods: We report the genetic construction and expression of a recombinant enzyme-linked antigen 
binding protein. A 50AD1 is monoclonal antibody raised against the rabies virus glycoprotein. The 
genes corresponding to antibody 50AD1 VH and VL fragments were cloned and assembled in synthetic 
gene coding for a single-chain antibody variable fragment (scFv). Then, the scFv gene was fused in 
frame with the gene of the bacterial alkaline phosphatase in a prokaryotic expression vector. 
Results: The scFv-alkaline phosphatase fusion protein was expressed in periplasm of recombinant 
bacteria and even released in culture medium. The soluble fusion protein preserved both IgG binding 
and alkaline phosphatase enzymatic activities as shown by native PAGE-immunoblotting, dot blot, 
ELISA and immunohistochemistry.  
Conclusion: This technology simplifies the production of immunotracers and has other advantages such 
as better fusion due the possibility of rapid single-step immunodetection. This new approach to the 
expression of an colorimetric antibody conjugate could lead to generate new reagent that be useful in 
the intensification of the follow-up of the actions of rabies control programs, such as epidemiological 
monitoring, or for the online monitoring of vaccine production. 
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CONNECTIONS: IMPLICATIONS FOR THE UNDERSTANDING OF RABIES 
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G. Ugolini 
Lab. Neurobiologie Cellulaire et Moléculaire, NBCM, UPR9040, CNRS, 91198 Gif-sur-Yvette, France 
In neurosciences, rabies virus (CVS strain) has become a very powerful tool for studying multisynaptic 
neuronal connections, due its ability to function as a self-replicating marker and to propagate 
exclusively between connected neurons by transneuronal transfer, which is strictly time-dependent. Our 
transneuronal tracing studies of rabies virus propagation in primates and rodents models (asymptomatic 
period) have provided valuable information on rabies pathogenesis. We have shown that rabies virus 
propagates by fast axonal transport at similar speeds in primates and rodents, after inoculation into the 
peripheral or central nervous system (CNS). Intracellular transport of rabies virus is preferentially 
addressed to neuronal dendrites rather then axons, since transneuronal transfer occurs only 
retrogradely, i.e., from dendrites of first infected neurons to presynaptic terminals of connected 
neurons. Rabies virus propagation occurs at chemical synapses, but not via gap junctions or local 
spread. Our results show that rabies virus receptors have a ubiquitous distribution on neurons within 
the CNS. Conversely, in the peripheral nervous system, rabies virus receptors are present only on motor 
endings, since uptake is restricted to motor endplates and axons of fast and slow motoneurons, whereas 
sensory and autonomic endings are not infected. Thus, after peripheral inoculations, motoneurons are 
the only gateway for rabies virus propagation to the CNS. Infection of sensory and autonomic neurons 
requires longer incubation times, since it reflects centrifugal propagation of rabies virus from the CNS 
to the periphery, i.e., it is the result of retrograde transneuronal transfer to sensory and autonomic 
terminals within the CNS. 
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INHIBITION OF RABIES VIRUS REPLICATION BY MICRO-RNA 
N.Israsena
1, N. Ratanasetyuth
2, P. Supavonwong
2, P. Virojanapirom
2 & T. Hemachudha
3 
1
  Department of Pharmacology, Chulalongkorn University Hospital 
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2
  Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand 
3  Department of Medicine, Chulalongkorn University Hospital 
Objective: To determine whether MicroRNA (miRNA) technology can be used to modulate rabies 
proteins synthesis and rabies virus replication. 
Methods: Neuro-2a cells were transfected with plasmid expressing miRNA designed against multiple 
location of rabies N, G mRNA, viral genome, and negative controls for 8 hours before challenged with 
rabies virus (CVS strain). Total RNA from the tranfected neuro-2a cells and supernatant were collected 
at 8, 24, and 48 hours after infection and quantified for rabies virus N,G,P mRNA, and viral genome 
using real-time PCR technique. Viral N and G proteins in the infected cell were analyzed by direct 
immunofluorescence assay (DFA) and western blot. 
Results: It was found that the miRNA against rabies virus N-protein mRNA(mi-N) effectively reduced 
amount of viral N,G mRNA in the cell and viral genome both in the cell and in the supernatant. Led to 
more than 95 % reduction in rabies genomic RNA compared to neuro-2a transfected with control 
miRNA vector. miRNA against rabies virus G-protein mRNA and viral genome were less effective in 
inhibiting viral replication. A marked decrease in virus titers from mi-N transfected neuro-2a cells 
compared to the control group was observed.  
Conclusions: These results indicate that miRNA against rabies N-protein mRNA have strong ability to 
inhibit rabies virus infection in cell culture and may have the potential to be used for therapy in clinical 
rabies.  
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Reference to an ancient Hindu picture of a snarling dog may be convincing enough proof to consider 
the fact that rabies has been known in the world for the past 50 centuries. Prior to the monumental 
observation about rabies of Fracastoro in the 16th century, facts and fantasies were intermingled in the 
study of rabies. In the realm of fantasy, consider the statement of Aristotle, (otherwise a great 
philosopher), that only animals and not man die of rabies. It took 19 centuries before Fracastoro finally 
established that infection with rabies is lethal for all warm-blooded beings including humans. The new 
era of rabies dates from the time of Galtier who isolated the virus and Pasteur who was able to create a 
somewhat attenuated strain of virus fixe which became the tool of laboratory studies for many decades 
after Pasteur.  
During the last 50 years of the past century, the knowledge of rabies was increased by leaps and 
bounds. First of all, using molecular biology as a tool it was possible to “take the virus apart” so to 
speak and describe and analyze all of its components. Establishment of multivariability among viruses 
as “de la rue” permitted not only a construct of a genetic linkage among lyssa family but also solved 
some puzzles of pathogenesis of rabies which defied solution when all work was concentrated on one 
laboratory strain of the virus. As an example, we know much more now about the genetic background 
regulating virulence of the virus. Also, it is now possible to use rabies as a vector of biological materials 
such as vaccines or sera.  
There is no progress in the treatment of the uniformly lethal disease. Perhaps, optimistically speaking, 
the 21st Century will bring us a glimmer of hope for the successful treatment of human rabies. 
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OIE GUIDELINES ON THE CONTROL OF DOG POPULATIONS 
S. Kahn
1, L. Stuardo
1 & S.A. Rahman
2 
1
  OIE Central Bureau, 12 rue de Prony, 75017, Paris, France 
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2  Retd. Dean Bangalore Veterinary College, No 123, 7th B Main Road 4th Block(West) Jayanagar, Bangalore 560 
011 INDIA 
At the 73rd General Session the OIE decided to develop guidance for Member Countries on humane 
methods for the control of stray dog populations. In 2006 an ad hoc Group was convened under the 
auspices of the OIE Permanent Animal Welfare Working Group. With valuable assistance from the OIE 
Collaborating Centre on Animal Welfare, a Questionnaire was developed and sent to OIE Member 
Countries, of which 81 countries submitted responses. In light of this information, the ad hoc Group 
prepared a first draft report, which notes the importance of controlling stray dog populations to help 
prevent zoonotic diseases and non-disease related nuisances to society and the environment. In 
choosing the preferred method of control, the risks to operators must be taken into account, as well as 
religious, cultural and economic contexts of the country. Depending on the situation, methods requiring 
individual animal restraint or methods for use at a distance may be recommended. While activities that 
aim to physically reduce the numbers of stray dogs are important, achievement of the long term goals 
of population control and avoidance of risks to human health depends on education of dog owners and 
the general public as to their responsibilities. The draft report notes that sub-national jurisdictions are 
often those responsible for the control of stray dog populations on the ground. The key role played by 
non-governmental organisations in stray dog management in many countries is acknowledged. The draft 
report emphasises that the close involvement of veterinarians and of official Veterinary Services, 
working in collaboration with public health authorities, is necessary to realise long term goals. 
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Looking backward, we continue to emphasize the fact that rabies is a very neglected totally preventable 
disease with the highest case fatality rate of any infectious disease known to man and 45 to 60 % of all 
human deaths occur in children. Unfortunately, rabies continues to receive very little attention on a 
global scale. Even the progress made to reduce, and in some cases eliminate, canine rabies from 
countries in Latin America has not received the international attention that it should have received. The 
reasons for the lack of international attention have always focused on the fact that the responsibility for 
rabies control is split between human health professionals and agricultural entities and the failure of 
governments in developing countries to recognize and support rabies prevention programs, both of 
which have lead to a lack of support and funds from international organizations. Although these are 
valid points, looking forward, it is time for all of us in the rabies community to join together globally 
and devise a different strategy for increasing global awareness of rabies focusing on the fact that rabies 
can be totally eliminated from the animal population. Rabies has many unique features that make its 
elimination a challenge but by using these challenges as a focal point for awareness we can 
dramatically increase global attention and consequently increase funding support for its elimination. It 
is only by working together that we will be successful. It is clear that we have all of the tools necessary 
to eliminate canine rabies. Together we can accomplish this goal by utilizing a four pronged approach 
which includes the use canine vaccination and control programs, increasing the availability of human 
rabies biologicals, increasing educational awareness for rabies prevention and lastly by involving 
governmental officials to assist in the implementation of programs. 
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DON’T FORGET RABIES WHEN YOU SETTLE ABROAD OR TRAVEL WITH 
CHILDREN 
M. Goudal
1 & Y. Rotivel
2 
1
  Rabies Treatment Center, Medical Center, Institut Pasteur, Paris, France 
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2  National Reference Center for Rabies, Institut Pasteur, Paris, France 
Human mortality from rabies is estimated to be about 55,000 deaths per year. Half of these deaths 
concern children who live in developing contires where rabies is enzootic. In France, among 20 cases of 
rabies in humans that occurred between 1970 and 2006, 10 were children less than 10 years old. All 
rabies cases were imported from rabies enzootic areas. A retrospective study was carried out in the 
population of children who received a Post-Exposure Prophylaxis (PEP) at the Pasteur Institute of Paris, 
after having been bitten or scratched by an animal while travelling in rabies enzootic countries. 204 
children from 6 months to 15 years old received PET:  
-  41% were exposed to dogs, 30% to cats and 16% to monkeys 
-  35% were less than 6 years old 
-  60% were boys.  
The majority of exposures happened to occur in North Africa (42%) and in Asia (27%). 
Medical recommendations and guidelines for preventive vaccinations of travellers visiting high endemic 
rabies areas and staying there a long time are necessary, especially for families with young children 
coming back to their native country. Primary pre-exposure immunization consists in 3 boosters (Day0, 
D7, D21 or D28). In case of exposure to rabies suspect animals, previously immunized subjects, 
especially children, only need 2 booster doses without administration of rabies immunoglobulin. This is 
very important for young children (around 3 years old) who often play with animals and who may escape 
the close surveillance of responsible adults. 
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DETERMINATION OF THERMOSTABILITY AND MELTING POINT OF THE BAIT 
CASING FOR THE VACCINE LYSVULPEN 
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Bioveta, a.s., Komenského 212, 683 23, Ivanovice na Hané, Czech Republic 
Modified live virus vaccines for oral vaccination of foxes aginast rabies shall both meet requirements of 
the European Pharmacopoeia monographs and should also take WHO and EU recommendations into 
account. The oral rabies virus vaccine LYSVULPEN produced by Bioveta is based on the attenuated 
rabies virus strain SAD Bern. One vaccination dose contains 1.8 x 107.0 TCID50 of vaccine virus. 
Objectives: The work was aimed at determining both the thermostability of the vaccine virus and the 
melting point of the bait casing according to EU recommendations. These factors directly influence the 
potency of vaccines under field conditions.  
Materials and Methods: Stability testing was performed under the following environmental conditions: 
The vaccine titre was determined at day 0 (initial titre) and day 7 after storage at 25°C. Stability of the 
bait casing was tested at 40 °C for 7 days. 
Results: The vaccine titre decreased by 0.4 log10 TCID50 after 7 days at 25°C. The bait casing 
remained intact under the test conditions. The melting point of bait casing is above 40°C. 
Discussion and Conclusions: The results obtained in relation with the 100% protective dose (1.8 x 
105.0 TCID50) as determined for the vaccine LYSVULPEN fulfil EU recommendations on 
thermostability. The vaccine titre at batch release should correspond to at least ten times the dose 
found to completely protect an experimental group (indicative 100% protective dose). The vaccine titre 
should not fall below the indicative 100% protective dose following exposure to 25 °C for 7 days. The 
stability of the bait casing also fulfils EU recommendations: the melting point of the bait casing is 
above 40°C. 
The LYSVULPEN vaccine has been successfully used for rabies control in a number of countries. The 
use of this vaccine resulted in a drastical decrease in rabies cases in Slovakia and elimination of rabies 
in the Czech Republic.  
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TEN-DAY OSERVATION OF LIVE-RABID DOGS 
V. Tepsumethanon, H. Wilde & V. Sitprija 
Queen Saovabha Memorial Institute, Bangkok 10330, Thailand  
(WHO Collaborating Centre for Research on Rabies Pathogenesis and Prevention) 
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Objectives: To analyze the ten-day observation and six criteria of live-rabid dogs.  
Materials and Methods: The Queen Saovabha Memorial Institute in Bangkok, Thailand, is an institution 
where owners bring rabies suspected dogs for observation in case the animals had either bitten a 
person, other animals or in case the animals show abnormal behavior or symptoms of unusual illness. If 
animals die, detection of rabies antigen in brain smears or impressions using fluorescent antibody 
testing (FAT) is routinely performed. If the animals survive the 10-day observation period, they are 
either released to owners or transferred to the municipal animal shelters.  
Retrospective and prospective data during the 10-day observations period were collected from 1,222 
dogs and 303 cats taken to our institute between 1985 and 2005. Six criteria were analyzed 
prospectively for 208 dogs developing rabies between 1997 and 2005: age; general condition (sick or 
healthy); day of sickness until admission; onset of diesease; progressiveness of illness during the last 3-
5 days and special clinical symptoms such as “circling” in the cage with hitting the head on the wall as 
if blind.  
Results: The experience with the implemented 10-day observation period confirms WHO 
recommendation on identifying suspected rabid dogs or cats under veterinary supervision after exposure 
to humans. All dogs and cats found rabid died within 10 days of observation. None of the dogs dying of 
rabies was younger than 1 month of age. All animals were considered healthy at the first day of 
observation, had a history of >10 days of illness before the first day of observation, and showed an 
acute onset of illness. During the last 3-5 days of illness (without treatment) clinical symptoms were 
stable or the disease was progressive. A striking clinical sign was “circling” as if the animals were 
blind. 
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A SIMPLE SANDWICH ELISA (WELYSSA) FOR THE DETECTION OF 
LYSSAVIRUS NUCLEOCAPSID IN RABIES SUSPECTED SPECIMENS USING 
MOUSE MONOCLONAL ANTIBODIES 
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G. Xu
1, P. Weber
2, Q. Hu
1, H. Xue
1, L. Audry
2, C. Li
1, J. Wu
1 & H. Bourhy
2 
1
  Wuhan Institute of Biological Products, Wuhan, Hubei Province, China, 430060 
2  UPRE Lyssavirus Dynamics and Host Adaptation, World Health Organization Collaborating Centre for Reference 
and Research and Research on Rabies, National Reference Centre for Rabies, Institut Pasteur, 28 rue du 
Docteur Roux, 75724 Paris Cedex 15, France 
Aims: To test a monoclonal antibody (MAb)-based capture enzyme-linked immunosorbent assays 
(WELYSSA) for the detection of lyssavirus nucleocapsid antigen on its sensitivity and specificity.  
Methods: Brain samples of different animal species were obtained from the UPRE Lyssavirus Dynamics 
and Host Adaptation department at Institut Pasteur, France. Among the tissue samples, 67 were 
positive and 963 were negative for rabies virus. All positive samples were characterized by partial or 
complete sequencing of the N gene and were selected that way to represent the genetic diversity of 
lyssaviruses circulating in Europe, Africa and Asia. The nucleocapsid of the PV strain was purified. A 
combination of four mouse monoclonal antibodies (MAb) directed against the rabies virus nucleocapsid 
was selected and used for the detection in ELISA. 
Results: Using prototype viruses from different genotypes of lyssaviruses and from various geographic 
origins and phylogenetic lineages, the threshold of the WELYSSA ELISA for the detection of lyssavirus 
nucleocapsids is low (0.8 ng/ml). With a panel of 1030 specimens received for rabies diagnostic 
testing, this test was found to be highly specific (0.999) and sensitive (0.970) when compared to other 
recommended rabies diagnostic methods. 
Conclusions: The test was optimized and standardized so that maximum concordance could be 
maintained with the standard procedures of rabies diagnosis recommended by the WHO expert 
committee. 
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RABIES RESEARCH TRENDS IN THE FGI “FEDERAL CENTRE FOR ANIMAL 
HEALTH” 
S.S. Rybakov, A.E. Metlin, A.V. Borisov, A.N. Balashov, A.A. Egorov & K.N. Gruzdev 
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Federal Governmental Institution “Federal Centre for Animal Health”, 600901, Yur’evets, Vladimir, Russia 
The FGI “Federal Centre for Animal Health” (FGI “ARRIAH”) is the All-Russia Research Centre for 
Rabies. The scope of activities comprises (i) animal rabies surveillance and diagnosis, (ii) improvement 
of rabies diagnostic tools and methods, (iii) production of anti-rabies vaccines and evaluation of their 
potency and safety, and (iv) molecular and biological characterisation of rabies viruses and vaccine 
strains. 
The following techniques are etsbalished for laboratory diagnosis of rabies: the fluorescent antibody test 
(FAT), mice inoculation test (MIT), the rabies tissue culture infection test (RTCIT), ELISA, latex 
agglutination, histological and immunohistochemical methods. Monoclonal antibodies and reverse 
transcriptase polymerase chain reaction (RT-PCR) followed by sequencing are used for the molecular 
and antigenic characterisation of rabies viruses.  
As a result of our work a commercially FAT rabies diagnostic kit has been produced. This kit contains 
all reagents needed to conduct FAT including buffer ingredients as well as positive and negative 
lyophilized control samples. Also, we have developed a direct liquid-phase FAT method for rabies 
diagnosis in brain samples conserved in formalin, which was patented in the Russian Federation. This 
method allowes testing of samples conserved in 10% formalin for at least 3 months. The FGI 
“ARRIAH” is an active partner in the Russian-Finnish Collaboration Program for the Control of Rabies 
in Wildlife. 
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RFFIT-MODIFIED ANTIBODY-BINDING TEST (ABTMR) AS A FAST AND 
REPRODUCIBLE TEST FOR DETERMINATION OF POTENCY OF INACTIVATED 
PURIFIED NON-ADJUVANTED RABIES VACCINES FOR HUMAN USE 
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S. Stankov, V. Simin, D. Vujin, U. Ungurović, N. Vranješ & J. Desnica 
Pasteur Institute, Hajduk Veljkova 1, 21000 Novi Sad, Serbia 
Aims/Objectives: Despite its serious drawbacks such as a low reproducibility, the considerable duration 
and the required number of about 100 mice per test sample, the NIH test is still the only 
internationally recognized potency test for inactivated rabies vaccines is. Promising results had 
previously been obtained with antibody-binding tests (ABT) as a possible replacement for NIH test. 
However, current versions of ABT are not suitable yet for vaccine batch release by national control 
laboratories due to specific adaptations to PCEC vaccine production systems. Here we present a 
modification of the ABT called RFFIT-modified ABT (ABTmR), which differs from current ABT in use of 
CVS strain and mouse neuroblastoma (MNA) cells in the second and third phase of the test, 
respectively.  
Materials and Methods: Test sensitivity is determined by the antigenic value of the test vaccine 
sufficient to yield fluorescent foci in the lowest dilution used. Reproducibility was assesed by 
comparing results for a single sample in eight consecutive tests. Furthermore, comparison of results 
obtained in ABTmR and NIH tests was done using four different samples of the Verorab and Rabipur 
vaccines. 
Results / Discussion / Conclusions: The total duration of ABTmR is 26-28 hours, confidence limits 
range from 78% to 129% of the estimated vaccine potency in IU/ml, and sensitivity is about 0.5 
IU/ml. In conclusion, the ABTmR is both a promising rapid and reproducible in vitro test for batch 
release of purified inactivated rabies vaccines and an in process control test for manufacturers of rabies 
vaccines. Therefore, it is a candidate for the replacement of the NIH test.  
_______________ 
Joint OIE/WHO/EU International Conference: “Towards the Elimination of Rabies in Eurasia” 
Paris (France), 27-30 May 2007  85 POSTERS 
 
COMPARATIVE ANALYSIS OF THE FULL GENOME SEQUENCE FOR EBLV -1 
AND -2 WITH OTHER LYSSAVIRUSES 
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1  Rabies & Wildlife Zoonoses Group, VLA - Weybridge), Surrey, United Kingdom 
2  Institute for Epidemiology, Friedrich-Loeffler-Institute, Wusterhausen, Germany 
3  Max-von-Pettenkofer Institute and Gene Center, Munich, Germany 
4  Unité de la Rage, Institut Pasteur, Paris, France 
We report the first full-length genomic sequences for European bat lyssavirus type-1 (EBLV-1) and 
type-2 (EBLV-2). The EBLV-1 genomic sequence was derived from a virus isolated from a Serotine bat 
in Hamburg, Germany in 1968 and the EBLV-2 sequence derived from a virus isolate from a human 
case of rabies that occurred in Scotland in 2002. A long distance PCR strategy was used to amplify the 
open-reading frames (ORFs), followed by standard and modified RACE (rapid amplification of cDNA 
ends) techniques to amplify the 3’ and 5’ ends. The lengths of each complete viral genome for EBLV-1 
and EBLV-2 were 11,966 and 11,930 base-pairs respectively and follow the standard rhabdovirus 
genome organisation of five viral proteins. Comparison with other lyssavirus sequences demonstrates 
variation in degrees of homology with the genomic termini showing a high degree of complementarity. 
The N-protein was the most conserved both intra- and intergenotypically, followed by the L-, M- and G- 
with the P-protein being the most variable. In addition, we have shown that both EBLVs utilise a 
conserved transcription termination and polyadenylation motif, approximately 50 nucleotides upstream 
of the L gene start methionine. All available lyssavirus sequences to date, including the EBLVs, use the 
second TTP site with the exception being Pasteur Virus (PV) and PV-derived isolates. This observation 
may explain differences in pathogenicity between lyssavirus strains, dependent on the length of the 
untranslated region, which might affect transcriptional activity and RNA stability. 
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OVERVIEW OF RABIES IN GREECE FROM 1966 TO 2006 
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The history and epidemiology of rabies in Greece from 1966 to 2006 is described. During the post – 
World War II period an increase of rabies cases was noticed in Greece with a peak in 1954 resulting in 
1,153 reported rabies cases. After this year, rabies cases drastically decreased until the detection of 
the last rabies case in year 1987.  
During the decades 1966-1975 and 1976-1985, a total of 1,036 and 39 rabies cases were reported, 
respectively. The majority of rabies cases in Greece were due to dog-mediated rabies; the last rabies 
case in wildlife was reported in a fox in 1974. In 1970, the last human case was reported and in 1987 
the last animal rabies case- a hunting dog- was reported from the prefecture of Evros, near the Turkish 
border. Since then, no human or animal rabies cases have been reported. 
All suspected domestic or wild animals submitted for rabies diagnosis during the period 1988-2006 
were negative. The fluorescent antibody test (FAT), mouse inoculation test (MIT) and the rabies tissue 
culture infection test (RTCIT) are standard techniques used for rabies diagnosis. Antigen detection 
ELISA was also applied when test kits were available. Compulsory vaccination campaigns of dogs and 
the low prevalence of rabies among wild animals resulted in rabies elimination from the country. As 
rabies is still present in neighboring countries Greek authorities are very precautious in the future. 
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BAYESIAN ESTIMATION OF RABIES AB-ELISA PERFORMANCES IN ABSENCE 
OF A GOLD STANDARD 
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Background: Today, international rabies control is based on antibody measurement after vaccination 
and relies partially on diagnostic tests interpretation. Unfortunately, it is admitted that there is no 
perfect reference test. 
Objectives: Bayesian approach for latent class analysis has been one of several statistical methods 
proposed to estimate tests parameters such as sensitivity and specificity. 
Material and Methods: Two European populations of vaccinated dogs and cats were used to determine 
the performances of two tests FAVN and ELISA. Estimation of prevalence, sensitivities and specificities 
of the two tests are obtained by combining data observed from populations to information from previous 
studies named informative priors. 
Results: Estimates of the sensitivities and prevalence were high (prevalence: 96.1%; FAVN sensitivity: 
98.9%; ELISA sensitivity: 93.8%) and are in agreement with previously published data. Estimations of 
the specificities were close to prior information and did not differ significantly between the two tests. 
Discussion: The results obtained underline the need for adequate informative priors in Bayesian 
estimations as well as the need for adequate sample size. Data suggest also that FAVN and ELISA 
specificities are often imperfectly determined. 
Conclusions: This innovative approach may be useful in designing improved tools in the Pet Travel 
Scheme.  
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THE FIRST CASE OF EUROPEAN BAT LYSSAVIRUS TYPE 1B INFECTION IN  
E. SEROTINUS IN POLAND 
M. Smreczak, A. Orłowska, P. Trebas & J.F. Zmudzinski 
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National Veterinary Research Institute, Virology Department, 24-100 Pulawy, Poland 
Aims/Objectives: For centuries, rabies has been present in many different species of terrestrial animals. 
In Poland in recent years, rabies virus was found in bats representing a risk for public health. The aim 
of the study was to describe the first isolation of EBLV-1b virus from bats in Poland and to compare its 
nucleoprotein sequence with sequences available in GenBank. 
Materials and Methods: In this study FAT positive bat brains submitted for rabies diagnosis from 
regional laboratories were analysed. All positive samples from the field were confirmed by mouse 
inoculation test (MIT) at the national reference laboratory for rabies at the National Veterinary Research 
Institute. EBLV-positive bat brains or first mouse passage brains were used for RNA extraction and 
subsequent hemi-nested RT-PCR (hnRT-PCR) amplification. Amplicons were subjected to sequencing 
in sense and anti-sense directions. The first 400 bp of nucleoproteine sequences were aligned using 
Clustal W programme with 22 N sequences available in the GenBank. Phylogenetic analysis was 
conducted with the DNA maximum likelihood method using BioEdit software (7.0.5 version).  
Results / Discussion / Conclusions: The hnRT-PCR amplified 410 bp products of the n-gene of EBLV-1. 
The phylogenetic analysis revealed that all bat rabies virus isolates belonged to EBLV-1 (genotype 5). 
The maximum likelihood method demonstrated that the EBLV-1 isolates could be divided into two 
phylogentic groups. One out of four isolates was similar to the subgroup EBLV-1b and formed a cluster 
with other known EBLV-1b isolates from Europe. This is the first case of isolation and identification of 
EBLV-1b type from serotine bats (Eptesicus serotinus) from Poland.  
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For Belgium only scarce data about bats were available before 2005. Conventional testing of dead 
found bats did not yield significant findings because of poor conservation conditions. During a 15 year 
period, only about 30 brains samples from bats were tested by IFI or RT-PCR; none were positive. 
Since 2005, active rabies surveillance in bats has been established to gain better information on the 
presence of bat rabies in Belgium. In order to cause minimal disturbances to the reproductive and 
social behaviour of the protected bat species, captures were carried out after the weaning of offsprings 
and before the hibernation from mid august to the first cold weather period, in front of the entrance of 
natural caves not used as nursery. In 2005, free-living bats were captured in 6 caves from Thierache 
and Haute Ardenne belonging to 6 different species (Myotis myotis, Myotis mystacinus brandtii, Myotis 
naterreri, Myotis bechsteinii, Myotis daubentonii and Plecotus spp). A total of 24 sera from 40 bats 
could be analysed for the presence of EBLV-1 antibodies. High EBLV-1 VNA (>1:100) were found in 1 
out of 8 Myotis myotis and 1 out of 8 Plecotus spp. Virus neutralising antibodies were also found at 
lower levels in 1 Myotis myotis and in 2 Myotis natererri.  
Those preliminary results underlined that serology is more sensitive than virology to control bat 
exposition to rabies virus and to have an index of virus circulation among bats. A better epidemiological 
description of the viral circulation(s) is necessary to assess the risk exposure of humans and domestic 
animal to bat rabies virus.  
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EXPERIMENTAL IMMUNIZATION OF CATS WITH A RECOMBINANT RABIES-
CANINE ADENOVIRUS VACCINE 
R.L. Hu, Y. Liu, S.F. Zhang & F. Zhang 
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Laboratory of Epidemiology, Veterinary Institute, Academy of Military Medical Sciences, 1068 Qinglong Road, 
Changchun 130062, P.R. China 
During the past decade, human rabies caused by cats has ranked the second highest in China. Several 
recombinant rabies vaccines have been developed for dogs. However, seldom have these vaccines been 
assessed or used in cats. In this trial, we report the experimental immunization of a recombinant 
canine adenovirus-rabies vaccine, CAV-2-E3∆-RGP, in cats. Thirty cats were inoculated with the 
recombinant vaccine intramuscularly, orally and intranasally. Safety and efficacy studies were 
undertaken using the fluorescent antibody virus neutralization (FAVN) test and evaluated. Results 
showed that this recombinant vaccine is safe for cats as demonstrated by the three different routes of 
administration. The vaccine stimulated an efficient humoral response in the vaccinated cats when 
108.5 PFU/ml of the recombinant vaccine was injected intramuscularly in a single dose. The 
neutralizing antibody level increased above 0.5 IU/ml at 4 weeks after the vaccination. The mean 
antibody level ranged from 0.96±0.26 to 4.47±1.57 IU/ml among individuals, and the antibody levels 
were elicited for at least 12 months. After this period, the immunized cats survived the challenge of 
CVS-24 and an obvious anemnestic and protective immune response was stimulated after the 
challenge. The immune response occurred later than the inactivated vaccine and the overall antibody 
level in the vaccinated cats was lower, but it was sufficient to confer protection of cats against 
infection. This demonstrated that a single, intramuscular dose of CAV-2-E3∆-RGP stimulated a long-
lasting protective immune response in cats and suggested that CAV-2-E3∆-RGP could be considered as 
a potential rabies vaccine candidate for cats. 
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PROFILE EPIDEMIOLOGIST AND MOLECULAR CHARACTERIZATION OF THE 
RABIES VIRUS DURING THE PERIOD OF 1996 – 2006 IN THE ESTATE OF 
MEXICO, MEXICO 
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Background: A concise description of the epidemiology of rabies virus in the State of Mexico, Mexico, 
and the characterisation of the rabies virus variants. 
Objective: To determine the seasonal incidence of human and animal rabies cases in the State of 
Mexico, Mexico, and to identify rabies virus variants circulating in the region.  
Materials and Methods: Brains samples from animals originating from the State of Mexico, Mexico, 
were forwarded to the State Laboratory of Public Health (LESP). Initially, brain specimens from 
different animal species were examined with the IFD. Specific identification of rabies virus variants 
(RABV) was performed using IFA. Kruskal-Wallis test was used to compare differences in the incidence 
of rabies cases between seasons of the year. 
Results: Between 1996 and 2006, a total of 14,588 brains samples were tested for the presence of 
rabies virus antigen, of which 190 samples (1.3%) were positive for rabies in IFD. Out of the 190 
rabies positive animals, 146 (76.8%) positive samples originated from dogs 32 (16.8%) from cows. 2 
(1.05%) from bats, 3 (1.6%) from humans, 2 (1.05%) from cats, 2 (1.05%) from pigs, 2 (1.05%) 
from sheeps, and 1 (0.5%) from mustelids. The characterization RABV identified 3 variants circulating 
in the State of Mexico with the majority of rabies cases (N=76; 74.29%) caused by variant V1, 
followed by variants V8 (22.86%) and V3 (2.86%). An analysis of the seasonal frequency of rabies 
cases during the year showed that 2.83%, 1.96% and 0.06% of the specimens submitted for rabies 
diagnosis to LESP in winter, spring and summer-autumn seasons, were rabies virus positive 
respectively. 
Conclusions: Rabies infections of terrestrial species occur in The State of Mexico, and disease 
transmission can persist at endemic levels for decades.  
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ACTIVE MONITORING OF EBLV INFECTION IN NATURAL BAT COLONIES 
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2  Dep. Biologia Animal, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain 
Bats are important reservoir hosts of RNA viruses, including lyssaviruses, which can cross the species 
barrier to infect humans and other domestic and wild non-flying mammals. Bats are primary lyssavirus 
reservoirs on all inhabited continents. Six of the seven Lyssavirus genotypes described to date infect 
bats. In Europe, two genotypes of Lyssavirus, European bat lyssavirus types 1 and 2 (EBLV-1 and 
EBLV-2), circulate among several bat species and numerous bats are found infected every year. To 
provide epidemiologists and public health officials with data to effectively implement public health 
measures, we have undertaken field studies to identify the temporal dynamics of virus infection in bat 
colonies by combining multidisciplinary approaches.  
We have focused our work on a long-term longitudinal survey of different bat colonies in the Balearic 
Islands. The prevalence of virus RNA and neutralizing antibodies was analysed in captured free-living 
bats. The bats were ringed to allow individual monitoring of infection and movements between colonies. 
Modelling was used to calculate the survival of bats during infection.  
The results show different lyssavirus infection episodes across a twelve year study period and no 
mortality of bats after infection. These findings have important implications on the monitoring of 
colonies where positive bats have been identified. 
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COMPARATIVE STUDIES OF AN INACTIVATED VACCINES AGAINST RABIES 
VIRUS IN VACCINATED GOATS  
N. Knezevic
1, S. Stankov
2, L.J. Veljovic
1, B. Djuricic
3, L.J. Lazarevic
2 & L.J. Pausak
1 
 
 
 
 
P
P
P
O
O
O
S
S
S
T
T
T
E
E
E
R
R
R
S
S
S
 
1
  Veterinarski zavod Zemun, Beograd, Serbia 
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In two separated studies we compared the imune responses of goats and lambs vaccinated with an 
inactivated antirabies vaccines produced in Serbia. 
Twenty adult goats and 9 lambs were vaccinated. The lambs were born to vaccinated goats and were 
tested in intervals of 26-52 days. Virus neutralising antibody (VNA) titers were determined for the 
period of 8 months after vaccination and/or 21 months after the second vaccination (booster) as well as 
10.5 months after third vaccination using RFFIT. 
Inactivated antirabies vaccine (RABIVET, Veterinarski Zavod Zemun) is based on PV strain of rabies 
virus (PARIS/BHK/ purified / 3 passages). The virus was propagated in BHK-21 C13 cells using roller 
bottles, subsequently inactivated using beta-propiolactone (0.04%) adsorbed on AlPO4 (1.5 mg/ml) 
and conserved with thiomerosal (0.01%). Three batches of RABIVET vaccine had AV of 1.3, 2.2 and 
10.4 IU/ml. An imported commercial vaccine had an AV of 7.4 IU/ml (NIH test). The AV of second lot 
of commercial vaccine was unknown. We concluded that imunological responses after first vaccination 
is poor with all vaccines used. Immune response was much better after the 2nd (21 months) and 3rd 
vaccination. In a second study, satisfactory level of VNA was achieved after the 1st vaccination, which 
lasted up to 6 months.  
Maternally transferred rabies antibodies were detected in 4 (44.4%) of 9 lambs. There was an 
impartially impaired immune response until day 52 psot partum. 
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PLATELIA
TM RABIES II: AN ELISA ASSAY USED FOR TITRATION OF RABIES 
GLYCOPROTEIN ANTIBODIES COMPARABLE TO THE REFERENCE METHOD 
RFFIT  
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centre for reference and research on rabies, Institut Pasteur, 25-28 rue du Dr Roux, 75015 Paris, France 
Rabies, one the major zoonotic diseases, remains an important but under-reported health problem in 
many countries, in particular developing countries. Current rabies vaccines or rabies infection induce 
the formation of antibodies directed to different viral proteins. Although virus-neutralising antibodies 
are not the only factor responsible for protection against rabies, their presence (mainly against the 
envelope glycoprotein) in serum is used as a relevant indicator of the degree of immunity in case of 
human pre-exposure rabies vaccination or during post-exposure treatment. 
Virus neutralisation tests (RFFIT / FAVN) are the current prescribed reference methods. But these 
methods are time-consuming, expensive, need very well-trained technicians and laboratory facilities in 
accordance with the need of handling live rabies virus. 
The PLATELIA
TM RABIES II is an ELISA assay based on titration of anti-glycoprotein antibodies in sera. 
This test may be the method of choice because it is simple (no need of specialised laboratory 
containment), safe (no use of life virus), and rapid (less than 4 hours) and can easily be automated.  
Sensitivity, specificity, linearity, accuracy of the test was evaluated using human serum samples from a 
total of 1348 vaccinated or non-vaccinated people. The results obtained with the ELISA were compared 
to results obtained with the RFFIT. The data generated indicate a linear relationship across the range of 
titration between the two methods and show that this new ELISA test is as sensitive and specific as the 
current standardized reference methods. The method is simple, safe, rapid and can be considered as a 
useful alternative to seroneutralisation assays.  
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PLATELIA
TM RABIES II: AN ELISA ASSAY TO COMPLETE CURRENT METHODS 
FOR TITRATION OF RABIES GLYCOPROTEIN ANTIBODIES IN ANIMAL 
SAMPLES  
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Yearly vaccination of dogs and cats as well as oral vaccination in foxes has been a major element for 
many countries to eradicate rabies from their territory. 
To assess the seroconversion after vaccination, measurement of the level of rabies anti-glycoprotein G 
antibodies is a relevant indicator. 
A new microplate assay, PLATELIA
TM RABIES II, for the detection and titration of these particular 
antibodies has been developed by Bio-Rad Company for a use on dogs, cats and foxes. 
An evaluation of PLATELIA
TM RABIES II has been performed on 1778 animals from different 
populations of dogs, cats and foxes in collaboration with the WHO/OIE/CRI rabies reference laboratory 
of AFSSA Nancy France. 
The results of this evaluation and the correlation with reference methods have been presented to the 
OIE scientific experts in 2006. 
As a result, PLATELIA
TM RABIES II is the first ELISA assay to have passed the Certification of 
Diagnostic Assay in regard to the OIE procedure. 
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DEVELOPMENT OF A SEQUENCE DATABASE FOR EUROPEAN BAT 
VARIANTS OF RABIES VIRUS IDENTIFIED IN EURASIA 
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Veterinary Laboratories Agency (Weybridge), Surrey, United Kingdom 
The European bat lyssaviruses (EBLV) type-1 and -2 (genotypes 5 and 6) are emerging zoonoses and 
have been known to infect not only their primary hosts (insectivorous bats) but on rare occasions other 
incidental animal hosts. EBLVs are bat variants of rabies virus that have evolved and adapted to bats 
between 5000 – 9000 years before rabies virus was identified in terrestrial mammals suggesting that 
spillover of rabies virus strains from Chiroptera to Carnivora has occurred. Molecular typing, particularly 
using the N- (nucleoprotein) and G- (glycoprotein) gene, provides epidemiological information regarding 
the geographical and host origins of the viruses analysed. The ability to derive useful information from 
virus sequence data is dependent upon the availability of an extensive database. Sequence and clinical 
information derived to date has been collated into a central European molecular epidemiological 
database [http://www.medvetnet.org/cms], which is freely accessible online to all researchers 
throughout Europe. This database will facilitate the interpretation and publication of sequence data to 
enable rapid genotyping of new viruses and provide a greater understanding of the geographical and 
host specific evolution of the European bat lyssaviruses. Additionally, genotyping viral isolates from 
European bats will act as an ‘early warning system’ to the emergence of new lyssavirus strains 
throughout Eurasia. 
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3  Guangdong Academy of Agricultural Sciences, Guangzhou 510640, China 
In 19 December of 2005 a rabies outbreak in pigs emerged in Yongzhou city of Hunan province where 
severe dog-associated human rabies is prevalent. The affected pig farm raised 56 fattening pigs in 4 
pens linked together in a line. The outbreak was initiated by a dog which was from the farmer’s 
neighbor and found to be acting strangely, roaming to pen 2 and leaving a bleeding bite on the snout of 
a pig through the pen wall bars. This injured pig developed a furious disease 20 days post exposure, 
then started to bite other pigs in the same herd. In following days the cases increased in pen 2 with a 
few furiously rabid pigs jumping the pen walls to bite pigs in the two flanking pens, triggering the 
rabies outbreak in 3 pens. The clinical manifestations included hyperexcitation, roaring and attack on 
other pigs within the herd. Some affected pigs exhibited spasms in response to tactile, auditory and 
visual stimuli, and some showed hydrophobia and fear of people. This outbreak resulted in 20 pig 
deaths which occurred 2 to 3 days following the appearance of symptoms. 
The cases were subjected to laboratory diagnoses and all tests showed positive results in the detection 
of rabies virus by fluorescent antibody test, mouse inoculation test and RT-PCR. The N gene-based 
phylogenetic analysis showed that the pig isolate was genetically close to the viruses circulating in 
dogs, indicating that the outbreak in swine was caused by that rabid dog. This was the first laboratory 
confirmed pig rabies in China. 
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Lelystad, The Netherlands 
2  Animal Sciences Group, Wageningen University Research Centre, Lelystad, The Netherlands 
Aims/Objectives: In rabies diagnosis a questionable Fluorescent Antibody Test (FAT) result or a negative 
FAT result with evidence of exposure of the animal to humans often needs to be confirmed by a Mouse 
Inoculation Test (MIT). To avoid animal experiments, the expensive and laborious MIT should be 
replaced by virus isolation in cell culture. Previously different groups described that virus isolation 
using murine neuroblastoma (MNA) cell culture for isolation of rabies street virus (genotype 1) is at 
least as sensitive as the MIT. The aim of the study was to investigate the sensitivity of MNA cells for 
EBLV isolation in comparison to MIT. 
Materials and Methods: EBLV was isolated from the brain of an Eptesicus serotinus (E.s.) bat. Ten-fold 
serial dilutions of EBLV of a virus stock were prepared in 10% brain suspensions from 11 non-infected 
E.s. bats. MIT was performed by intercerebral injection of 30 µl suspension in 5 mice for each virus 
dilution. Virus isolation was performed by mixing 30 µl suspension with 2.25x104 MNA cells in 150 µl 
DMEM/1%strep/1%fungizone/10%FCS/0.005 %(w/v) DEAE-dextran. After incubation for 4 days at 
35ºC and 5% CO2 cells were fixed in 80% acetone and stained with anti-rabies FITC-conjugate. MID50 
(mouse infective dose) and TCID50 were calculated according to Spearman & Kärber. 
Results: The table summarizes the results of the experiments: 
virus dilution:  10
-2 10
-3 10
-4 10
-5 10
-6  blanc 
Experiment 1: 
MIT (10 wks old mice)  3† of 3  5† of 5  3† of 4  0† of 4  0† of 4  0† of 4 
cell culture  5+ of 5  5+ of 5  5+ of 5  1+ of 5  0+ of 5  0+ of 5 
Experiment 2: 
MIT (baby mice)  5† of 5  5† of 5  5† of 5  0† of 5  1† of 5  0† of 5 
cell culture  5+ of 5  5+ of 5  5+ of 5  4+ of 5  0+ of 5  0+ of 5 
 
Based on the results as presented in the table, the following infective doses were calculated: 
Experiment 1: MID50/ml = 5.6 and TICD50/ml = 5.8 
Experiment 2: MID50/ml = 6.0 and TICD50/ml = 6.6 
Conclusion: Based on the results obtained it can be concluded that virus isolation on MNA cells is at 
least as sensitive as MIT in demonstrating the presence of European Bat Lyssavirus (EBLV) in brain 
tissue of E.s. bats. 
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2  Federal Ministry for Health and Women 1030 Vienna 
This report gives a graphic description of the ongoing and successful rabies eradication program in 
Austria which is performed by the National Reference Laboratory at the AGES Institute for Veterinary 
Disease Control at Moedling and supported by the BMGF (Federal Ministry for Health and Women). This 
rabies eradication program is based on oral vaccination of foxes, monitoring of vaccination campaigns 
(bait uptake and seroconversion) and rabies surveillance. 
Interruption of rabies transmission from terrestrial animals to other terrestrial animals and to humans 
using oral vaccination of foxes is now a successful tool in rabies control. The results of intensive rabies 
surveillance in wildlife and domestic animals in Austria of the last years are presented. For this purpose 
different diagnostic tools such as the Fluorescence Antibody Test (FAT), Immunohistochemistry (IHC), 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Virus Isolation in Cell Culture are 
applied. This report gives an overview of the eradication as well as of preventive measures, their 
efficiency and side effects, and the tools to check the efficiency of these measures in terms of 
Fluorescence Antibody Virus Neutralisation Test (FAVNT), Enzyme Linked Immunosorbent Assay 
(ELISA) and FAT.  
We share our experiences with the use of a life attenuated rabies virus vaccine and the difficulties of 
establishing blood sampling in foxes. Results obtained with an ELISA technique to evaluate the 
efficiency (seroconversion) of the vaccination programme in foxes are shown. Finally, the costs spent 
for vaccination, surveillance, diagnosis, and eradication measurements per year are presented. 
_______________ 
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A RABIES CELL PHONE ADVISORY SYSTEM: A CULTURALLY TARGETED 
TOOL DESIGNED TO REDUCE HUMAN RABIES SUFFERING IN THE 
PHILIPPINES 
 
 
 
 
P
P
P
O
O
O
S
S
S
T
T
T
E
E
E
R
R
R
S
S
S
 
E. Adriano
1, M. Vinluan
2 & S.J. Scholand
3 
1  ARF World Philippines, Quezon City, Philippines 
2  Department of Health, Manila, Philippines 
3  A Rabies Free World, Philadelphia, United States of America 
Morbidity and mortality from human rabies in the Philippines remains high. Major factors responsible 
for the continued problem include lack of knowledge regarding aspects of disease prevention, perceived 
high cost of treatments, cultural inhibitions to legitimate medical care, as well as finite resources. In 
resource constrained areas where rabies is endemic, low cost technologies developed to address these 
issues could reduce suffering by providing information to make more intelligent decisions. 
We sought to develop a cell phone tool to disseminate information about rabies to the people of the 
Philippines. We envisioned users of the system to increase their understanding of rabies so as to more 
appropriately access existing health resources.  
We contracted a private company to develop a cell phone accessible information system designed to 
provide basic information about rabies. Through “text messaging”, users can download to their cell 
phone information on rabies including: rabies prevention, rabies prevalence, disease basics, appropriate 
treatment for potential rabies exposures, and animal and dog information. Additionally, the system 
provides the location of Department of Health (DOH) approved Animal Bite Treatment Centers and 
Bureau of Animal Industry recognized veterinary diagnostic laboratories. 
The three major telephone carriers in the Philippines now support this tool, with the potential to reach 
up to 20 million cell phone users. Promotional efforts to make the tool more widely known are ongoing. 
Future studies to assess the impact of the rabies cell phone advisory system in terms of health access 
and utilization are planned.  
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In Poland, for decades the predominant rabies reservoir has been the red fox (Vulpes vulpes). However, 
since the last decade rabies in the raccoon dog (Nyctereutes procyonoides) has been of increasing 
concern. Therefore, it is of utmost importance to determine the role of this species in epidemiology of 
rabies in certain parts of the country. The implementation of the oral rabies vaccination (ORV) of foxes 
significantly influenced the epidemiological situation of rabies. ORV was implemented at the western 
border of Poland in 1993 and successively expanded eastwards in subsequent years to eventually cover 
the entire territory of Poland in 2002. 
The purpose of this study is to assess possible key factors contributing to the maintenance of rabies in 
raccoon dogs in Poland. We investigated the following variables predictive of rabies incidence in 
raccoon dogs on a district level: (i) rabies incidence in foxes, (ii) raccoon dog population density, (iii) 
time for initiation of ORV in years, (iv) calendar year and (v) variant of genotype 1 rabies virus 
circulating in a given area. During the years 2003-2006 incidence of raccoon dog and fox rabies 
ranged from 0 - 4.25 and 0 – 6.4 cases per 10, 000, respectively. Results of a multivariate analysis 
indicate that the time from initiation of ORV is the most influential factor causing a 34% decrease in 
racoon dog rabies incidence per each additional year of vaccination. Independently, an increase of 1 
case per 10,000 in fox rabies incidence resulted in an approximately 4% increase in raccoon dog 
incidence. The virus variant seems to play less significant role. 
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IMPLEMENTATION OF ULTRA-LIGHT AIRCRAFTS IN BAITS DISTRIBUTION 
FOR PER-ORAL VACCINATION OF VENISON AGAINST RABIES 
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  Dr. Sinkovic Mirko, Zoo graden - Palic, Republic of Serbia 
2  Prof. Dr. Bosiljka Djuricic, Faculty of Veterinary Medicine, Belgrade, Republic of Serbia 
3  Dr. Dusan Lalosevic, Medical Faculty, Novi Sad, Republic of Serbia 
For many years rabies has been present in the northern part of the Backa region, Serbia. The number of 
rabies positive animals ranged between 1 – 16 per year with the majority of rabies cases found in foxes 
followed by cats and dogs. Based on its topography, the North Backa region is considered an ideal 
habitat for foxes with an estimated population of 1400 to 2200. Considering the fact that the fox is the 
main rabies reservoir in Serbia oral rabies vaccination (ORV) of foxes was launched by distributing 
vaccine baits using ultra-light aircrafts.  
Materials and Methods: A total of 20,000 vaccine baits were used for ORV (donation of Pharmaceutical 
Company “Virbac”, SAG 1 oral, in ampoules with 1,75 ml suspension content, with concentration 10 
7.5 GKID 50/ml). The vaccine baits were stored at -20°C prior to distribution in the field. The 
vaccination area comprised two lakes (Palicko lake and Ludosko lake) and one nature conservation area 
(Selevenjska forest) considered ideal habitats for foxes, birds and other wild animals. Vaccine baits 
were distributed during five days in February 2002 using ultra-light aircrafts of the local aero-club in 
Subotica. The temperatures were around + 4ºC without snow. Bait density was 18 – 24 vaccine baits 
per km². 
Results and Discussion: In the following 16 months, in the territory of Subotica, only one case of fox 
with rabies was reported. During the next two years, the number of foxes increased resulting in an 
increase in the number of fox rabies cases in regions outside of the vaccinated territory. Based on our 
experience using ultra-light aircrafts the distribution of vaccine baits and screening of foxes habitats is 
more exact and easier simply because the speed of the aircraft is lower and maneuver abilities are 
better. Minimal logistic support, simple and easy maintaining and easy movement (if necessary) make 
ultra-light aircrafts an alternative choice for aerial distribution of baits. Logistic and media support is 
needed and proved helpful.  
Conclusion: ORV using aerial distribution of vaccine baits was implemented for the first time in Serbia, 
Subotica community. ORV is the method of choice for use in the whole Republic taking experiences of 
other countries into account. The use of ultra-light aircrafts is cost-effective and easy to perform under 
field conditions.  
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RETROSPECTIVE ANALYSIS OF 174 HUMANS WHO RECEIVED P.E.P. (RABIES 
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  Rabies Treatment Center, Medical Center, Institut Pasteur, Paris, France 
WHO recommends the use of RIG and vaccine for severely exposed (category III) subjects. The 
possibility of an interference of RIG and antibodies elicited by inactivated vaccine has been reported. 
To evaluate this eefect the Rabies Treatment Center of the Pasteur Institute in Paris decided to 
prescribe antibody titration to patients who received RIG and vaccine simultaneously. Detection of 
rabies specific antibodies was conducted using the Platelia rabies II test on Evolis Automat during 
routine testing. 
During a two years period (2005 and 2006) 174 persons were given both RIG and vaccine against 
rabies. A total of 154 antibody titrations (88.5%) were performed on the last day of treatment. 
Antibody titers as determined by ELISA were greater than 1 UE/ml for 133 patients and correspondent 
treatments were finished. For 13 patients the antibody titers ranged between 0.5 and 1 UE/ml resulting 
in an additional vaccine shot for 6 patients. Four of the 6 developed an antibody titer between 2.1 and 
4.9 UE/ml after the second antibody titration. The antibody titers were less than 0.5UE/ml for 8 
patients. Six persons received an additional vaccine shot developed antibody titers between 0.9 and 
5.5 UE/ml. 
In conclusion: 
Rabies serology seems to be unnecessary for most of the patients who received PEP including RIG and 
vaccine. Therefore, we recommend antibody titration only in special cases: 
- patients more than 50 years old,  
- immunocompromised patients, 
- patients who received low vaccine potency or unvalidated regimen,  
- patients who received high dose of immunoglobulin. 
Serology should be preferably performed one week after the end of the treatment.  
_______________ 
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EPIDEMIOLOGY OF RABIES IN THE KYRGYZ REPUBLIC 
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Of all officially registered cases of rabies at agricultural animals revealed in 2005 makes 23.7% and in 
2006 33.3% of cases, of dogs is 63.2% and 58.7% correspondingly, and of other wild animal (wolves, 
foxes, rats, cats, etc.) to 13.2% and 8%. 
Rabies among of wild animals is widespread mainly in southern areas of republic. Here the greater 
density of wild animals which is essential above than in other areas is observed.  
The epidemiological data of Department of State veterinary of the Ministry of Agriculture admits that 
rabies is registered both of domestic and of wild animals. As the analysis shows - dogs are prevailing 
source of danger.  
The purposes of carrying out of our researches is organization of referent laboratory on rabies, equipped 
by the modern labware; epidemiological monitoring; training of experts to modern methods of 
diagnostics; development of the scientifically-proved program of control of rabies in the Kyrgyz 
Republic. One of the primary goals is equipment by the modern equipment for diagnostics of rabies of 
the Osh regional veterinary laboratory and training of its personnel as the largest on the population in 
southern region of republic with purpose to provide control of this infection in this region. 
Therefore for further epidemiological research of rabies especially in wild and domestic carnivores’ 
animals is necessary. The knowledge of an area of distribution of rabies then can be used to advance 
adequate measures of preventive maintenance for the people and domestic animals. 
_______________ 
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ANTIBODY RESPONSE IN ITALIAN DOGS VACCINATED WITH INACTIVATED 
VACCINES 
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Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise “G. Caporale”, Teramo, Italy 
To prevent the introduction of rabies into free areas, the European Union Commission set out the 
health rules for trade in dogs and cats between EU Member States. In particular, pet owners should 
have their dogs identified by microchip implantation and protected against rabies by vaccination with 
inactivated vaccines. The test recommended by the World Organization for Animal Health (OIE) to 
detect rabies antibodies in carnivores is the Fluorescent Antibody Virus Neutralization (FAVN). Only 
officially authorized laboratories are allowed to monitor the sera for determining the antibody titers for 
rabies before moving the animals to foreign Countries. The Istituto Zooprofilattico Sperimentale 
dell’Abruzzo e del Molise has been authorised and routinely perform such a test since 2000. 
A two year period study on the immune response in pets following rabies vaccination was realized. The 
serum titer was determined according to the FAVN test procedure and results analyzed to evaluate the 
antibody dynamic following vaccination. Four hundreds twenty six dogs were included in the study and 
four groups were formed based on the time of serum collection. 
Four hundreds eleven animals had detectable level (0.5 U.I./ml) of neutralising antibodies against 
rabies and no differences (P>0.05) were found between groups. Conversely, when the mean values of 
the antibody titres found in the four groups were compared, animals of the group A showed higher 
(P<0.05) titers related to those found in other three groups. 
_______________ 
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